CURRICULUM VITAE

Name: Howard M. Sandler, M.D., M.S. Business Data: Address: CSMC Department of Radiation Oncology, 8700 Beverly Blvd., AC 1022 Los Angeles, CA 90048

Telephone: (310) 423-4204 Education: 9/1970-6/74 Windham High School, Willimantic, CT 9/1974-5/78 University of Connecticut; B.S., Summa Cum Laude 9/1978-6/85 University of Connecticut; M.D. 9/1978-12/91 University of Connecticut; M.S. (Physics)

Licensure: State of Pennsylvania, 1986 State of Michigan, 1989 State of Alabama, 1994 State of Colorado, 1994 Board Certification: Radiation Oncology, 1989 Professional Experience: Postdoctoral Training 7/1985-6/86 Intern St. Francis Hospital and Medical Center, Hartford, CT

7/1986-6/89 Resident Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

7/1988-6/89 Chief Resident Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

Academic Appointments

1986-89 Assistant Instructor, University of Pennsylvania University of Michigan 1989-95 Assistant Professor, Radiation Oncology 1995-2001 Associate Professor with Tenure, Radiation Oncology 2001-2008 Professor, Radiation Oncology 2003-2008 Professor, Urology 2007-2008 Newman Family Professor of Radiation Oncology Cedars-Sinai Medical Center 2009- Professor of Radiation Oncology 2009- Ronald H. Bloom Family Chair in Cancer Therapeutics

Academic Administrative Appointments University of Michigan

1994-97 Clinical Division Director, Radiation Oncology 1997-2003 Associate Chair for Clinical Research, Radiation Oncology 2003-2008 Senior Associate Chair, Radiation Oncology 2000-2008 Departmental Service Chief Cedars-Sinai Medical Center 2008- Chairman, Department of Radiation Oncology

Clinical/Hospital Appointments

1997-2008 Executive Medical Director, Radiation Oncology Alliance, Lansing, MI 2000-2008 Board of Directors 2001-2008 Board of Directors, Northeast Michigan Cancer Center, Alpena, MI 2005-2008 Board of Directors, Central Michigan Community Hospital Radiation Oncology,

Mt. Pleasant, MI 2008- Cedars-Sinai Medical Center, Los Angeles, CA

Professional Activities: Editorial Boards 1994-97 Journal of Clinical Oncology 2008-13 Journal of Clinical Oncology

1997-2001 The Prostate Journal 2000-01 Oncology.com 2003 Urologic Oncology: Seminars and Original Investigations 2003- Medscape Hematology-Oncology 2007 ASCO Clinical Cancer Advances 2007 2008 Prostate Cancer Infolink 2008-09 Clinical Genitourinary Cancer 2010- Clinical Genitourinary Cancer 2008- The Journal of Medicine 2009- Urologic Oncology (Radiation Oncology Topic Editor) 2011- OBR Daily 2013- Vice Chair of the Male Genital Expert Panel, 8

th Edition AJCC Cancer Staging

Manual Study Sections/Workshops/Panels

1999 Participant, Prostate Cancer State-of-the-Science Workshop, National Cancer Institute 2000 Participant, Superficial Bladder Cancer State-of-the-Science Workshop, National Cancer Institute 2003- External Advisor, Synergy Consortium Targeting New Therapeutics for Lethal

Phenotypes of Prostate Cancer 2004 Ad Hoc Reviewer, DoD Prostate Cancer Research Program, PCRP Integration

Panel 2005 Ad Hoc Member of FDA-ODAC (Oncology Drug Advisory Panel) 2005 PSA Working Group Participant, Program for the Assessment of Clinical Cancer

Tests (PACCT), Cancer Diagnosis Program, National Cancer Institute 2006- External Reviewer for CTEP Phase III Clinical Trial Concepts 2006 CTEP Renal Cancer Strategy Session 2006-07 Study Section, RFA CA 07-503 Advanced Technology Radiation Therapy Clinical

Trials Support (ATC) 2006 NCI Workshop on Advanced Technologies in Radiation Oncology, Invited

Speaker 2006-07 Medical Officer, CDRH, FDA (6 months appointment during academic sabbatical) 2007- DoD Prostate Cancer Research Program, PCRP Integration Panel 2009 Ad Hoc Reviewer, American Cancer Society International Fellowships for

Beginning Investigators applications 2009 Consultant, FDA-CDRH Advisory Panel re: localized prostate cancer 2010-11 Prostate Cancer Foundation (PCF) Research Awards Standing Review

Committee 2010 NCI Cellular & Tissue Biology P01 Study Section, Ad Hoc Reviewer 2010-11 NCI Symptom Management and Health-Related Quality of Life Steering

Committee (SxQOL SC) Clinical Trials Planning Meeting (CTPM): Building Bridges: the Identification of Core Symptom and Health-Related Quality of Life Domains for use in Cancer Research, Planning Committee Member

2011 NCI Novel Neoadjuvant Therapy for Bladder Cancer Workshop, Invited Panel Moderator

2012 Ad Hoc Member of FDA-ODAC (Oncology Drug Advisory Panel) 2013 Member, FDA Workshop at AUA meeting, “Prostate Cancer Endpoints” 2013 Study Section, NCI National Clinical Trials Network (U10)

Manuscript Reviewer International Journal of Radiation Oncology Biology Physics Journal of Neurosurgery The Cancer Journal from Scientific American Journal of Clinical Oncology

Urology Journal of Urology The Lancet JAMA Nature Clinical Practice Urology European Urology Medical Dosimetry Cancer Practical Radiation Oncology BJU International Committee Service: International

2006- SANTRO (Sino-American Network for Therapeutic Radiology and Oncology Advisory Board of Directors

Committee Service: National 1991-97 Southwest Oncology Group, Brain Committee 1994-97 Southwest Oncology Group, Vice Chairman, Brain Committee 1991- Southwest Oncology Group, GU Committee 1993- Radiation Therapy Oncology Group

1995-97 Radiation Therapy Oncology Group, Chair, 3D Committee 1997- Radiation Therapy Oncology Group, Chair, Genitourinary Committee 1997- Examiner, Oral Board Examination, American Board of Radiology, Intermittent

1997-2003 NCCN Kidney/Testicular Panel 1997-2008 NCCN Prostate Cancer Panel 1998-2000 Genitourinary Cancer Subcommittee, ASCO Program Committee 1998- ASCO Localized Prostate Cancer Expert Panel

1999-2004 ASTRO Health Services Research Committee 2003-2008 ASTRO Education Committee 2003-05, 09-10 ASTRO Annual Meeting Abstract Reviewer 2004-05 ASCO-ASTRO-SUO Prostate Cancer Symposium, Program and Steering

Committees 2006 ASTRO Advocacy Day Participant, Washington, DC 2006-09 ASCO Cancer Communications Committee 2006- ASTRO Member, Prostate Cancer Work Group, AUA-Physician Consortium for

Performance Improvement 2007-10 ASTRO Evidence-based Clinical Practice Guideline Panel: Role of Post-

Operative Radiotherapy for Radical Prostatectomy, Research Council 2007-13 ASCO-ASTRO-SUO Genitourinary Cancer Symposium, Program

Committee/Steering Committee Scientific Program Chair 2010 Meeting

2007- ASCO People Living With Cancer Genitourinary Cancer Advisory Panel 2007- ASTRO Government Relations Committee 2007- ASTRO FDA Subcommittee, Government Relations Council 2009- Chair, FDA Subcommittee 2007- ASTRO Emerging Technology Monitoring Subcommittee, Clinical Affairs and

Quality Council 2007 ASCO Pilot Tester for Cancer Prevention MOC module 2008-2009 AACR/ASCO Workshop on Methods in Clinical Cancer Research, Vail, CO,

Program Committee 2008 ASCO Cost of Cancer Care Task Force, Patient Resources Subcommittee 2009- ASTRO Chair of Prostate/GU Resource Panel, Clinical Affairs and Quality

Committee 2010-2012 ASCO/ESPN Prostate Cancer Advisory Panel “Men and Prostate Cancer” 2011- ASCO CancerProgress.Net: An Interactive History of Cancer Research

Advances, Co-Executive Editor 2012- American Board of Radiology, Chairman, GU Category Committee 2012 SUO Scientific Program Planning Committee, Prostate Cancer Session 2012- ASCO Genitourinary Guidelines Advisory Group (GAG)

Committee Service: State 2004- Michigan Cancer Consortium Advisory Committee on Prostate Cancer Committee Service: Institutions

University of Michigan 1990-2008 The University of Michigan Comprehensive Cancer Center 1991-96 Radiation Oncology Total Quality Team 1992-98 Cancer Work Group Committee 1994-95 Northeast Ann Arbor Planning Council 1994-2008 Department of Radiation Oncology Promotions Committee 1998-2008 Chair 1996-2008 Departmental Compliance Officer

1997-2004 University of Michigan Comprehensive Cancer Center Protocol Review Committee 1998-2003 Chair, Protocol Review Committee 1998-2001 Medical School Advisory Committee on Appointments, Promotions, and Tenure (ACAPT)

1999 Neuroradiology Fellowship Internal Review Committee 1999 Urology Residency Internal Review Committee 1999-2001 Center for Clinical Investigation and Therapeutics (CCIT) Advisory Committee 1999-2004 University of Michigan Health System Cancer Center Network, Advisory Board 2000-08 Departmental Billing Officer 2000-08 Departmental Service Chief 2002-08 Medical School Admissions Committee 2003, 2005 Ad Hoc Medical School Advisory Committee on Appointments, Promotions, and

Tenure (ACAPT) 2003-04 Senate Assembly Budget Study Committee 2004-06 Executive Board Member, Michigan Urology Center 2004-08 University of Michigan Comprehensive Cancer Center Data and Safety

Monitoring Board 2005-06 Clinical Research Billing Advisory Panel 2006, 2008 Provost Promotions Casebook Reviewer 2006 Urology Chair Search Committee 2006-08 Clinical Research Informatics Advisory Committee (CRIAC) 2007-08 Advisory Council on Clinical Research Cedars-Sinai Medical Center 2008- Executive Management Committee 2008- Medical Executive Committee 2008- Quality Council 2008- Medical Leadership Group 2008- Clinical Improvement Committee 2009 Protocol Review and Monitoring Committee Development Committee, Chair 2009- Radiation Safety Committee, Co-Chair 2009- Cancer Quality Steering Committee 2010- Medical Director, SOCCI Clinical Research Office 2010- Institutional Biosafety Committee, Co-Chair 2011- Core Member, Samuel Oschin Comprehensive Cancer Institute 2013- Board of Directors Medical Policy Committee

Professional Associations and Scholarly Societies: 1990- American Society of Therapeutic Radiology and Oncology

American Society of Clinical Oncology American Urological Association 1992-2008 Michigan Society of Therapeutic Radiologists Radiation Therapy Oncology Group Southwest Oncology Group 2009- Society of Urologic Oncology 2009- Southern California Radiation Oncology Society Military Service: None

Honors and Special Awards: 1976 Phi Beta Kappa 1977 University of Connecticut Alumni Scholar 1988 American Cancer Society Clinical Oncology Fellow

1991 ESTRO Travel Grant 1994-2006 Named in “Best Doctors in America 1996 Named in “Best Doctors in America: Midwest Region, 1996-1997”

2003 Teacher-of-the-Year in the Department of Radiation Oncology 2010 Named Fellow of the American Society of Radiation Oncology (FASTRO)

Research Grants and Fellowships Received:

Current (Sandler) 1/1/02-12/31/08 1.32 Calendar Months Radiation Therapy Oncology Group $217,720 RTOG Membership RTOG Committee Chair $16,346 This project is for the University of Michigan to become an affiliate member of the Radiation Therapy Oncology Group.

Submitted

Yale – Re-Submission R01 CA164841-01 (Gross) 7/01/12-6/30/17 0.75 Calendar Months NIH/NCI $221,515

Comparative Effectiveness of Radiation Therapy for Cancer of the Prostate The goal of this proposal is to perform clinical study to compare two different radiotherapy strategies for localized prostate cancer.

RTOG – P01 P01 PAR-09-025 (Knudsen) 4/01/12-3/31/17 1.20 Calendar Months

NIH/NCI $265,948 Molecular Determinants of the DNA Damage and Hormone Therapy Response in Prostate

Cancer The goal of this proposal is to translate the laboratory findings of radiation enhancement to the

clinic. Previous

Co-Investigator National Institutes of Health (5P01CA 42761-03), “Antimetabolite Selectivity: Regional Treatment/Modulation”; 8/01/88 - 7/31/91 (Effort: 10%) ($981,654 direct cost) Co-Principal Investigator National Institutes of Health (1 R01 CA55256-01), “Surgery for Spinal Cord Compression Due to Cancer”; 9/01/92 - 8/30/97 (Effort: 0%) ($1,022,910 direct cost) Co-Investigator National Institutes of Health (1 R01 CA59412-01), “Validation of Automatic Segmentation Algorithms”; 4/01/93 - 3/31/96 (Effort: 0%) ($372,364 direct cost) Collaborating Investigator National Institutes of Health (2 R01 CA51397-05), “A Clinical, Real-Time, a-Si:H Radiotherapy Portal Imager”; 2/01/93 - 1/31/97 (Effort: 5% years 3, 4, 5) ($1,813,582 direct cost) Principal Investigator National Institutes of Health (5 U01 CA60279-02), “3-D Dose Escalation for Prostate Cancer”; 1/04/93 - 3/31/97 (Effort: 10%) ($269,616 direct cost) Co-Investigator National Institutes of Health (1 P01 CA59827-01), “Optimization of High Dose Conformal Therapy”; 4/01/93 - 3/30/98 (Effort: 9% yr 4) ($3,015,430 direct cost)

Co-Investigator National Institutes of Health/National Cancer Institute (CA 69568-01), “SPORE in Prostate Cancer Research”, Sub-project: Inhibition of Human Prostate Cancer Metastasis by Modified Citrus Pectin”, 9/30/95-7/31/98 (Effort 5%) ($126,875 direct cost) Principal Investigator Schering-Plough, “Randomized trial comparing dose-escalated external beam conformal boost vs. brachytherapy boost in patients with intermediate risk adenocarcinoma of the prostate” (Effort 0%) ($42,735 direct cost) (Study designed and written at Univ. of Michigan) Co-Investigator National Institutes of Health R01, “Online Setup and Monitoring of Conformal RT using AMFPIs” 12/01/99-11/30/02 (Effort 5%) ($454,107 direct cost), Kwok Lam, PI Online setup of conformal RT using AMFPIs The goal of this research project is to study the use of solid-state, on-line imagers to assist with patient setup during radiotherapy Clinical Trial (Sandler) 3/7/2003-12/31/03 0% Calypso Medical Technologies $10,000 Testing Agreement Test and evaluate certain technologies associated with the development of a medical device to be used in connection with radiation therapy treatment.

Co-Investigator Smith Kline Beecham, “Phase I study of adjuvant chemotherapy with topotecan and oral etoposide after involved field chemo-radiotherapy for malignant brainstem gliomas” (Effort 2%) ($20,172 direct cost), Patricia Robertson, PI The major goals of this project are to determine the maximum tolerated dose of daily topotecan used in conjunction with standard dose, conformally delivered external beam radiotherapy. Co-Investigator Southwest Oncology Group (2 U10 CA 27057-19) 04/01/04-12/31/08 (Effort 2%) NIH/NCI ($174,175 direct cost) The major goals allow the University of Michigan to continue to participate in the activities and study protocols of the Southwest Oncology Group, which involve development and testing of investigational therapies in patients with solid tumor or hematologic malignancies that have less than 100% cure rates with standard therapies. 2 P01 CA59827 (Fraass) 8/1/00-07/31/06 NCTX 3% NIH/NCI $349,746 Optimization of high dose conformal therapy Project 4: Clinical studies of high dose conformal therapy

The major goal of this project is to continue to further escalate tumor doses and maximize normal tissue sparing in patients treated with radiation therapy for cancer. Role: Co-Investigator

1 R01 CA95662 (Wei) 1/1/04-6/30/08 NCTX .36 Calendar Months NIH/NCI $600,299 Survivor QOL & spouse satisfaction after prostate therapy

The major goals of this project are to prospectively evaluate quality of life of prostate cancer patients following prostate cancer surgery and prostate cancer radiation therapy.

P50 CA69568 (Pienta) 7/1/03-5/31/08 .60 Calendar Months NIH/NCI $595,023 Spore in Prostate Cancer

The SPORE is dedicated to translating bench discoveries to patients with prostate cancer as rapidly as possible. The projects within the SPORE range from the study of racial differences in prostate cancer to the discovery of new genes related to prostate cancer diagnosis and prognosis. In addition, the SPORE provides infrastructure to the prostate cancer researchers at the University of Michigan, including extensive tissue collections and longitudinal patient databases.

R21 CA110518 (Taylor) 9/01/05-8/31/08 .60 Calendar Months NIH/NCI $198,410 PSA Based Early Detection of Prostate Cancer Recurrence The goal of this proposal is to detect recurrence of prostate cancer early enough based on serial

PSA. B06-43939 (Sandler) 12/15/06-12/14/08 .47 Calendar Months Sanofi Aventis $233,184 A Phase II Prostate Cancer Trial of Weekly Docetaxel and Salvage Radiation Therapy for Biochemical Failure after Radical Prostatectomy This study will follow weekly doses of docetaxel and salvage radiation therapy for biochemical failure after radical prostatectomy. (Sandler) R21 CA110485-01A1 09/01/06-8/31/08 .97Calendar Months NIH/NCI $159,750 Intratreatment monitoring of prostate movement during radiotherapy This proposal seeks to facilitate high dose radiation therapy for patients with prostate cancer. The specific aims are to determine the impact of movement on 1) dose to the prostate and 2) dose to the rectal wall. The data from this study will support a subsequent Phase II trial to establish tumor control as well as morbidity reduction in radiotherapy treatments monitored and gated to minimize intratreatment prostate movement.

Teaching Activities: National

1996 Exam Question Creator, Radiation Oncology Self-Assessment Program 1998-2000 Meet the Professor Luncheon, Annual ASTRO Meeting 2000 ASTRO Workshop: Clinical Implementation of 3-D Conformal Radiation Therapy

for Prostate Cancer, Chicago, June 16-18, 2000 2004- American Board of Radiology Angoff Exam Reviewer 2008-09 Methods in Clinical Cancer Research, AACR/ASCO Workshop, Vail, CO, Faculty

and Program Committee 2013- University of Connecticut Career Advisor Program

University of Michigan

1991 Co-Course Director, Clinical Neuro-Oncology Course, The University of Michigan Medical School, Ann Arbor, Michigan, June 27-29, 1991.

1994- Medical Director, The School of Radiation Therapy Technology, lectures given annually and responsible for assigning topics to other faculty 1994-97 Director, Residency Program, Department of Radiation Oncology 1996, 1999 Lecture on Radiotherapy Principles, University of Michigan Medical Oncology

Fellowship 1998-99 Fellowship mentor, John Fiveash, M.D. (current position: Asst Prof Univ

Alabama) 2000 Judge, Providence Hospital Resident Research Day 2002 Lecture on Prostate Cancer for Minimed School, April 9, 2002 2002-04 Dissertation Committee, Menggang Yu, Ph.D. Candidate in Biostatistics 2004- M1 Shadowing Program 2006-7 3 Invited educational sessions with NCI Radiation Oncology Residents

Invited Lectures/Presentations: Extramural Invited Presentations

“Dose Escalation for Stage C Prostate Cancer,” Visiting Professor, Mayo Clinic Scottsdale, Scottsdale, AZ, April 11, 1991.

“Dose Escalation for Stage C Prostate Cancer,” Visiting Professor, Fox Chase Cancer Center, Philadelphia, PA, June 12-13, 1991,

“Conformal External Radiation in the Treatment of Prostate Cancer - Techniques and Results,” Booth Memorial Medical Center - Prostate Cancer: Detection, Diagnosis and the Role of 3D

Conformal Radiation Therapy, Flushing, NY, April 16, 1993.

“Other Radiation Therapies,” American Brain Tumor Association - 1993 Brain Tumor Symposium, Chicago, IL, May 22, 1993.

“Recent Advances in Radiation Oncology -Firing Directly at the Tumor While Aiming to Reduce Side Effects,” Fourth Annual Hematology-Oncology Update - 1993, Hartford, CT, October 7, 1993,

“The University of Michigan Experience: 3D CRT for Brain Tumors,” Twenty-Ninth Annual San Francisco Cancer Symposium, San Francisco, CA, February 26-27, 1994.

“The University of Michigan Experience: 3D CRT for Prostate Cancer,” Twenty-Ninth Annual San Francisco Cancer Symposium, San Francisco, CA, February 26-27, 1994.

Clinical Oncology Association of Georgia (COAG), Atlanta, GA, April 27, 1994.

ASTRO Plenary Session Discussant, San Francisco, CA, October 4-7, 1994.

Visiting Professor, Bowman Gray Medical School, Winston-Salem, NC, November 11, 1994.

RSNA Refresher Course: Prostate Cancer, Chicago, IL, November 28-30, 1994-1996.

ASCO Slide Session Discussant, Los Angeles, CA, May 22-24, 1995.

Visiting Professor, Johns Hopkins Oncology Center, Baltimore, MD, September 14-15, 1995.

“Does 3-D Conformal Radiation Therapy Make a Difference,” Michigan Urological Society Meeting, Novi, MI, January 10, 1996.

“Clinical Experience with 3-D Planning - Brain Tumors”, Principles and Practice of 3-D Radiation Treatment Planning, Munich, Germany, March 21-23, 1996.

“PSA Following Irradiation for Prostate Cancer -- University of Michigan Experience”, ASTRO Symposium on PSA Following Irradiation for Prostate Cancer, San Antonio, TX, September 28, 1996.

“Radiation Therapy - Biochemical Progression Free Survival” and “RT + Hormone Blockade: RTOG and EORTC Data”, PAACT Prostate Cancer Conference, Grand Rapids, MI, October 26, 1996.

“External Radiation Therapy in Early Stage (RP-Eligible) Patients” Presidents Categorical Course on Prostate Cancer, ASTRO Annual Meeting, Los Angeles, CA, October 27, 1996.

“Potential Treatment Gains Offered by Optimization of Dose Distributions -- Clinical Overview” Scientific Session, RTOG Semi-annual Meeting, Houston, TX, February 22, 1997.

Panelist, Workshop on Proton Therapy, Midwest Proton Radiation Institute, Indianapolis, IN, August 9, 1997.

Discussion Panelist, ASTRO Symposium on Prostate Cancer, Atlanta, GA, September 6, 1997.

“New Developments in External Beam Radiation Therapy” American Cancer Society Prostate Cancer Public Forum 97, San Diego, CA, September 13, 1997.

“Dose Escalation for Prostate Cancer” and “Dose Escalation for Malignant Gliomas”, Providence Health System, Portland, OR, September 26, 1997.

ASTRO Oral Presentation Discussant, Orlando, FL, October 22, 1997.

“Radiation Therapy for Prostate Cancer”, Advances in Genitourinary Oncology, Grand Rapids CCOP, Grand Rapids, MI, November 12, 1997.

“Radiotherapy for Prostate Cancer,” Bay Medical Center Prostate Cancer Support Group, Bay City, MI, February 3, 1998.

“Bladder Preservation Strategies,” “Current Investigations of the RTOG Genitourinary Group,” and “Dose Escalation for Malignant Gliomas,” Special Guest Faculty at the Second Annual Mayo Radiation Oncology Symposium, Scottsdale, AZ, February 6-7, 1998.

“New Approaches for a New Millennium: Prostate Brachytherapy”, Panelist, Radium Society Annual Meeting, Monaco, May 4, 1998.

“Conformal Radiotherapy at the University of Michigan”, Groupe Lyonnais D'Oncologie et Radiotherapie (GLOR), Lyon, France, May 6, 1998.

“Comprehensive Review of Radiation Therapy for Carcinoma of the Prostate”, Annual Meeting of Michigan Society of Hematology and Oncology, Novi, MI, September 25, 1998.

“Dose Escalation Trials and Outcome for Lung Cancer”, 3-D Radiation Treatment: Technological Innovations and Clinical Results, Munich, Germany, March 26, 1999.

“Dose Escalation Trials – Outcome and Toxicity for Prostate Cancer”, 3-D Radiation Treatment: Technological Innovations and Clinical Results, Munich, Germany, March 27, 1999.

Prostate Cancer Abstract Discussant, ASCO, Atlanta, GA, May 16, 1999

Visiting Professor, Princess Margaret Hospital, Toronto, Canada, February 8-10, 2000

“Update of NCCN Prostate Cancer Guidelines”, NCCN Annual Meeting, Ft. Lauderdale, March 17, 2000.

“Treatment Options for Early Prostate Cancer”, Advances in Cancer Care of the Non-Oncologist, Jackson, MI, April 15, 2000.

“Dose Escalation for Prostate Cancer: Which Dose for Which Person?”, Controversies in Uro-Oncology, 5

th International Symposium on Special Aspects of Radiotherapy, Berlin, Germany,

May 12, 2000.

“Role of Radiotherapy Following Radical Prostatectomy”, Munson Medical Center Grand Rounds, Traverse City, MI, June 30, 2000.

“High Dose Conformal XRT is the Standard Therapy for Prostate Cancer”, Southern Association for Oncology Annual Meeting, Asheville, NC, August 10, 2000.

“Conformal External Beam Radiotherapy for Prostate Cancer”, 12

th Annual Cancer Conference,

Memorial Hospital, Colorado Springs, CO, October 13, 2000.

“External Beam – 3D Conformal Therapy/IMRT”, Cancer of the Prostate, Ohio State University, Columbus, OH, May 5, 2001.

“Radiotherapy for Prostate Cancer”, Grand Rounds, Hackley Hospital, Muskegon, MI, November 26, 2001.

“Radiotherapy for Prostate Cancer – A Team Player”, AACR Special Conference in Cancer Research: New Discoveries in Prostate Cancer Biology and Treatment, Naples, FL, December 7, 2001.

“RTOG Clinical Trials Involving Radiotherapy and Prostate Cancer: Answering Important Survival Questions”, 12

th International Prostate Cancer Update, Keystone, CO, February 2002.

“Brachytherapy vs. External Beam Radiotherapy” and “Hormone Therapy and Radiation Therapy”, 3

rd National Prostate Cancer Symposium, Melbourne, Australia, August 22-23, 2002.

“Prostate Cancer and the Advocacy Community”, Advocacy Committee, RTOG Semi-Annual Meeting, Houston, January 24, 2003.

“Radiotherapy or Surgery for Younger Men with Prostate Cancer”, 13

th International Prostate

Cancer Update, Vail, February 22, 2003.

“Radiotherapy for GU malignancies: A Team Player”, ASTRO Spring Refresher Course, Chicago, April 5, 2003.

“Update on RTOG Trials for Prostate Cancer”, SWOG Semi-Annual Meeting, San Diego, April 10, 2003.

“Can Biochemical Failure (ASTRO Definition) Be Used as a Surrogate Endpoint for Prostate Cancer Survival in Phase III Localized Prostate Cancer Clinical Trials? Analysis of RTOG Protocol 92-02” Publications Scientific Session, RTOG Semi-Annual Meeting, Montreal, June 28, 2003.

“Postoperative Radiotherapy”, 14

th International Prostate Cancer Update, Vail, February 3-6,

2004.

Invited Discussant on Bladder Preservation, ASCO Annual Meeting, New Orleans, June 7, 2004.

“Best of ASCO-AACR”, Panelist, ASTRO Annual Meeting, Atlanta, October 2004

Invited Discussant on External Beam Radiotherapy for Prostate Cancer, ASTRO Annual Meeting, Atlanta, October 2004

Keynote Speaker, GU Radiation Oncologists of Canada: Prostate Cancer Radiotherapy 2004, Toronto, November 11, 2004.

Guest Faculty, “Adjuvant and Salvage Radiotherapy for Prostate Cancer: Current Status”, 4

th

Annual Multidisciplinary Genitourinary Oncology Course, Cleveland Clinic, November 18, 2004.

Keynote Speaker, RTOG Semiannual Meeting, Phoenix, January 22, 2005.

Hospital-wide Grand Rounds, “IMRT for Prostate Cancer: The Gentle Touch of the Artist’s Paintbrush”, Munson Hospital, Traverse City, MI, February 4, 2005.

ASCO Multidisciplinary Educational Session, “Radiation Therapy as Part of the Management of High-Risk Disease (Prostate Cancer)”, Orlando, May 13-14, 2005.

ASCO Multidisciplinary Education Session, “Bladder Preservation Strategies”, Orlando, May 13-14, 2005.

Fifth International Prostate Cancer Congress, “Radiotherapy Update: Focus on External Beam”, San Juan, PR, July 2, 2005.

CAP Educational Session, “Biochemical Failure Definitions after Radiotherapy for Prostate Cancer”, Chicago, September 14, 2005.

ASTRO Educational Session, “Treatment Planning for Prostate Cancer: Imaging, (US,CT, MR), Immobilization, Fields, Tumor and Normal Doses”, Denver, October 18, 2005.

Sixth Annual SUO Meeting, “Definitions of Biochemical Failure after Radiation: Past Problems and Future Solutions”, Washington, DC, December 2, 2005.

Guest Faculty, Kukuna-o-ka-la Annual Meeting, Kona, HI Feb, 2006.

ASCO Multidisciplinary Education Session, “Bladder Preservation Strategies”, Atlanta, June 3, 2006.

ASCO Update Course, Thomas Jefferson Hospital, Philadelphia, June 17, 2006.

Sixth International Prostate Cancer Congress, “Radiotherapy Updates”, Boca Raton, July 21, 2006.

2

nd Oncology Congress, Program Committee and Faculty, New York, NY, October 21, 2006.

Sixth Cambridge Conference on Innovations and Challenges in Prostate Cancer, Faculty, Cambridge, MA, October 30, 2006.

ASTRO Educational Session, “Treatment Planning for Prostate Cancer: Imaging, (US,CT, MR), Immobilization, Fields, Tumor and Normal Doses”, Philadelphia, November 7, 2006.

ASTRO FDA Panel, “Physician-Scientist Perspective”, Philadelphia, November 7, 2006.

ASTRO Special Lecture, “How RTOG Has and Will Further Change Your Practice”, ASCO-ASTRO-SUO Prostate Cancer Symposium, Orlando, February 23, 2007.

Invited Faculty, UCLA Annual State of the Art Urology Conference, Marina Del Rey, March 9-11, 2007.

“Postoperative Radiotherapy for Prostate Cancer”, GU Oncology Conference, Dana-Farber Cancer Center, Boston, May 2, 2007.

“Perspectives on Chemotherapy for Prostate Cancer”, San Francisco Radiation Oncology Conference, July 7, 2007.

“Combined Modality Therapy for Common Malignancies: Bladder Cancer”, 19

th Annual Fall

Foliage Cancer Conference, Asheville, NC, October 20, 2007.

“Treatment Planning for Prostate Cancer”, Refresher Course, 49th Annual ASTRO Meeting, Los

Angeles, October 28, 2007

“Active Surveillance Is Equivalent to Surgery or Radiotherapy in Low Risk Disease”, Debate Co-chair, First European Multidisciplinary Meeting on Urological Cancers, Barcelona, November 2, 2007.

“The Best Treatment of Locally Advanced Prostate Cancer is: Radiation Therapy and Hormones”, Debate participant, First CURy Congress, Barcelona, February 2, 2008.

Invited panelist, Public Forum, ASCO-ASTRO-SUO Genitourinary Cancer Symposium, February 13, 2008.

“Radiation Therapy: How Much Androgen Deprivation Therapy is Enough?” ASCO-ASTRO-SUO Genitourinary Cancer Symposium, San Francisco, February 14, 2008.

“Prostate Cancer Update” and “Bladder Cancer/Testicular Cancer Update”, ASTRO Spring Refresher Course, Houston, April 4, 2008.

“Treatment Planning for Prostate Cancer”, Refresher Course, 50

th Annual ASTRO Meeting,

Boston, October 2008

“ASTRO 2009 IMRT/Proton Therapy Symposium”, Invited faculty member, Phoenix, January 23-24, 2009.

“Prostate IMRT Treatment Planning”, Spring AAMD Meeting, Skamania, WA, March 21, 2009.

“Optimal Management of Locally Advanced Bladder Cancer”, Educational Panel, ASCO Annual Meeting, June 1, 2009.

“Bladder-sparing Treatment Approaches”, Oncology Congress 5

th Annual Meeting, San

Francisco, September 24, 2009.

“Treatment Planning for Prostate Cancer”, Refresher Course, 51th Annual ASTRO Meeting,

Chicago, November 3, 2009.

“Short-term Endocrine Therapy Prior to and During RT Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA<20: Initial Results of RTOG 94-08”, 10

th

Annual SUO Meeting, NIH, Bethesda, December 3, 2009.

“Prostate Cancer: Role of Postoperative Radiotherapy”, Visiting Professor, UT-Southwestern Department of Radiation Oncology, Dallas, TX, February 19, 2010.

“Update of RTOG GU Trials”, GU Oncology Conference, Dana-Farber Cancer Center, Boston, MA, June 16, 2010.

“Dose Escalation and Prostate Cancer”, Plenary discussant, RTOG Semiannual meeting, Philadelphia, June 19, 2010.

Invited plenary discussant, 52

nd ASTRO Annual meeting, San Diego, November 1, 2010.

Debate: All Patients Should Receive Adjuvant Radiotherapy for All Radical Prostatectomy Positive Surgical Margins, Pro: Howard Sandler, Con: Peter Scardino, 11

th Annual

Society of Urologic Oncology Meeting, Bethesda, MD, December 10, 2010.

Visiting Professor, Department of Radiation Oncology, University of Pennsylvania, January 26, 2011.

“Prostate Cancer 101”, IMPaCT DoD CDMRP Meeting, Orlando, March 10, 2011.

“Best Form of Monotherapy for Low Risk Prostate Cancer: IMRT”, UCSF Annual Radiation Oncology Update, San Francisco, April 2, 2011.

“Protons, Photons and Brachytherapy for Prostate Cancer: Pros and Cons”, Speaker/Panelist, ABS Annual Meeting, San Diego, April 16, 2011.

“Post-prostatectomy radiation therapy: adjuvant or salvage?”, 12

th Australasian Prostate Cancer

Conference 2011, Melbourne, August 3, 2011.

“ASTRO IHE-RO Workshop”, Speaker, FDA, White Oak, MD, September 9, 2011.

53rd

Annual ASTRO Meeting, Miami, FL: Invited ARRO Poster Walk Professor and Moderator/Speaker for Panel: Is There an Optimal Approach to High Risk Prostate Cancer Management? The Need for Multidisciplinary Care, October 3 and 5, 2011.

“Seminar on Highlights from the 2012 GU Cancer Symposium”, Live webinar sponsored by ASCO, March 29, 2012.

Invited Faculty, Five lectures given, 18

th Annual Kukuna-o-ka-la Radiation Oncology Conference,

Maui, HI, February 19-22, 2013. “Endpoints for clinical trials of WGA with radiotherapy: Clinical significance of/FDA confidence in biopsy results and PSA changes”, Clinical Trials for Focal Therapy/Whole-Gland Ablation in Localized Prostate Cancer, Memorial-Sloan Kettering Cancer Center, New York, March 8, 2013. “Comparing Current Options in Radiation Therapy”, 6th Annual Interdisciplinary Prostate Cancer Congress, New York, March 16, 2013. “Advances in Genomics for Cancer Clinical Trials”, session moderator, RTOG Symposium, Philadelphia, June 14, 2013.

Intramural/Local Invited Presentations Michigan

“Update on Radiation Therapy for Malignant Gliomas, Neurosurgery Grand Rounds, The University of Michigan Medical Center, Ann Arbor, Michigan, October 9, 1991.

“A Dose Escalation Trial in Prostate Cancer Using 3-D Planning,” U.S. - Japan Radiation Oncology Conference, The University of Michigan Medical Center, Ann Arbor, Michigan, November 21-23, 1991.

“Prostate Cancer: Finding it, Staging it, Treating it,” Quint LE, Bree RL, Grossman HB, Sandler HM, Radiology Grand Rounds, The University of Michigan Medical Center, Ann Arbor, Michigan, December 10, 1992.

“Radiotherapy for CNS Neoplasms: Principles and Practice,” Neurosurgery Grand Rounds, The University of Michigan Medical Center, Ann Arbor, Michigan, January 13, 1993.

“Stereotactic Radiosurgery,” Ophthalmology Grand Rounds, December 8, 1994.

“Update on 3D Conformal Radiotherapy Research,” Genitourinary Conference, April 18, 1995.

“Radiation Therapy for Prostatectomy-eligible Prostate Cancer,” GU Oncology Conference, March 11, 1997.

“Radiation Therapy for Bladder Cancer,” GU Oncology Conference, November 11, 1997.

“Radiotherapy for Prostate Cancer,” University of Michigan Prostate Cancer Support Group, January 8, 1998.

“External Beam Radiation for Localized Prostate Cancer”, 1

st International Prostate Cancer

Symposium for the Patient, Ann Arbor, MI, July 31, 1998.

“External Beam and Brachytherapy for Prostate Cancer,” 2nd

Annual Prostate Cancer Symposium for the Patient, Ann Arbor, MI, July 17, 1999.

“Detection and Radiotherapy for Prostate Cancer”, Cancer Answer Night, Livonia, MI, October 5, 1999.

“Localized Bladder Cancer Shootout: Surgery or Radiation?”, GU Oncology Conference, March 14, 2000.

“GU Cancer”, Interpreting Clinical Data: Highlights from ASCO 2000, June 10, 2000.

“Radiation Therapy Clinical Trials in Early Prostate Cancer”, GU Oncology Conference, June 13, 2000.

“External Beam Radiotherapy for Prostate Cancer: Dose Escalation Using 3D CRT”, Department of Radiation Oncology Grand Rounds, November 16, 2000.

“Radiosurgery”, Neurosurgery Grand Rounds, May 30, 2001.

“Prostate Cancer”, School of Nursing, July 10, 2001.

“Radiation for Non-melanoma skin Cancer”, Dermatology Residents, July 11, 2001.

“Real Men Get It: What Every Man Should Know About Prostate Cancer”, Cancer Answer Night, Livonia, MI, November 8, 2001.

“Radiation for Non-melanoma skin Cancer”, Dermatology Residents, March 3, 2003.

“Radiotherapy or Surgery for Younger Men with Prostate Cancer”, GU Oncology Conference, May 15, 2003.

“Radiation for Non-melanoma skin Cancer”, Dermatology Residents, April 26, 2004.

“Update on Radiotherapy for Prostate Cancer”, University of Michigan Prostate Cancer Support Group, September 1, 2005.

“Radiation Oncology Basics”, Urology Fellows, March 17, 2006.

“IMRT for Prostate Cancer”, Central Michigan Community Hospital, April 27, 2006.

“Radiation for Non-melanoma skin Cancer”, Dermatology Residents, August 27, 2007.

“Prostate Cancer: Focus on External Beam and Brachytherapy”, St. Joseph’s Hospital Prostate Cancer Support Group, September 20, 2007.

“Aspects of Radiotherapy for Prostate Cancer”, Downriver Cancer Support Group, January 15, 2008.

“Prostate Cancer and Organ Motion”, Gilda’s Club Metro Detroit, February 7, 2008.

“Proton Therapy”, MRT Work Group Meeting (CON Subcommittee), Lansing, February 12, 2008.

“Radiotherapy and GU Malignancies”, Urology Residents, February 28, 2008.

Cedars-Sinai/Los Angeles Region

“What’s New in Radiation Therapy”, 2009 Cedars-Sinai Neurosciences Symposium, Marina Del Rey, February 14, 2009.

“Cutting Edge Issues in Prostate Radiotherapy”, Cutting Edge Medical Advances: Impacting Your Health, Palm Springs, March 17, 2009.

“Role of Radiation Therapy after Surgery”, Urology COE Grand Rounds, March 19, 2009.

“Update on Radiation Oncology Department”, Cancer Center Advisory Council, April 6, 2009.

Panel Discussion: Prostate Cancer, 31

st Annual Bernard Strauss Urology Day, June 11, 2009.

Host/Speaker, 22

nd Annual Cedars Sinai Cancer Survivors Day, June 12, 2009.

“Role of Radiation Therapy”, Outsmarting Brain Tumors: A Conference on Brain Tumors for Patients, Families and Caregivers, June 13, 2009.

“ASCO GU Update”, Hematology Oncology Grand Rounds, June 30, 2009.

“Radiation Therapy for Non-Melanoma Skin Cancer”, Invited speaker, UCLA Department of Dermatology Grand Rounds, July 7, 2009.

Presenter, General Oncology Tumor Board, October 7, 2009.

Presenter, General Oncology Tumor Board, June 23, 2010.

“Craniopharyngiomas”, Neuro-Oncology Tumor Board, July 14, 2010.

Faculty, 2010 Clinical and Translational Research Workshop, August 9-13, 2010.

Cancer Center Education Committee, “Prostate Cancer 2010: Updates, Advances, Future Directions”, September 21, 2010.

“Reirradiation with Curative Options”, Practical Management of Sinus Disease, Hyperparathyroidism and Thyroid and Head and Neck Cancers Symposium, March 13, 2011.

“Image-Guidance and Prostate Radiotherapy”, Image Guided Diagnosis and Treatment

Symposium, Westin-LAX, March 27, 2011.

“Prostate IGRT”, CEU Lecture for Radiation Therapists, April 21, 2011.

“Post-operative Radiation Therapy for Prostate Cancer”, Urology Grand Rounds, UC-Irvine, April 25, 2011. “Role of Radiation Therapy”, Outsmarting Brain Tumors: A Conference on Brain Tumors for Patients, Families and Caregivers, May 14, 2011. “Update on RTOG GU Clinical Trials”, Pathology Grand Rounds, Cedars-Sinai, May 27, 2011. “Clinical Investigator Responsibilities/Ethics”, Clinical & Translational Research Workshop, July 28, 2011. “Bladder Preservation”, Urology Grand Rounds, UC-Irvine, August 15, 2011.

“Ask the Experts” and “Case-based Roundtable”, PCRI Prostate Cancer Conference, Westin-LAX, September 11, 2011. “Advances in Patient Positioning for the Prostate”, Emerging Technologies Clinical Forum, Beverly Hills, March 21, 2012. “Multimodality Cancer Therapy: Working Together”, Cedars-Sinai CME Event, Course Director and Speaker, March 23-24, 2012. Presenter, City-wide Prostate Cancer Journal Club, Santa Monica, September 12, 2012. Speaker, Blue September Prostate Cancer Awareness Event, Los Angeles City Hall, September 13, 2012. “VMAT and Motion Management during Prostate Cancer Treatment”, Southern California Society of Radiation Therapists Annual Meeting, Cedars-Sinai, September 15, 2012.

“Radiation Therapy and Kidney Cancer”, Kidney Cancer Support Group, Cedars-Sinai Cancer Center, October 8, 2012.

“Update on Postoperative Radiation Therapy for Prostate Cancer”, Kaiser-Sunset, March 5, 2013. “Why Consider Radiation Therapy”, Prostate Cancer Update, Cedars-Sinai Medical Center, April 13, 2013. Faculty/Speaker, Clinical & Translational Research Workshop: Grant & Clinical Protocol Development, Cedars-Sinai, July 22-26, 2013. “New Radiotherapy Approaches for Personalized Medicine”, 2

nd Annual New Therapeutics in

Oncology, Cedars-Sinai Medical Center, November 9, 2013.

Bibliography/Publications: Completed Publications in Scientific Journals Peer-Reviewed Publications

1. Sandler H, Hanks G: Analysis of the possibility that transurethral resection promotes metastasis in prostate cancer. Cancer 62:2622-2627, 1988. PMID: 3191464.

2. Chu JCH, Sandler HM, Curran WJ, Shammo G, Stafford PM, Richter MP, Hanks GE:

Intraoral hyperthermia using microwave antennae and a dental mould. Endocurietherapy/Hyperthermia Oncology 5:121-125, 1989.

3. Sandler HM, Rubenstein JH, Fowble BL, Sergott RC, Savino PJ, Bosley TM: Results of radiotherapy for thyroid ophthalmopathy. Int J Radiat Oncol Biol Phys 17:823-827, 1989. PMID: 2777672. 4. McKenna WG, Weiss MC, Bakanauskas VJ, Sandler HM, Kelsten ML, Biaglow J, Tuttle SW, Endlich B, Ling CC, Muschel RJ: The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18:849-859, 1990. PMID: 2182580. 5. Sandler HM, Curran WJ, Turrisi AT: The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 19:9-13, 1990. PMID: 2166020. 6. Liang BC, Thornton AF, Sandler HM, Greenberg HS: Malignant astrocytomas: Focal tumor recurrence after focal external beam radiation therapy (FEBRT). Journal of Neurosurgery 75:559-563, 1991. PMID: 1653309. 7. Sandler HM, McShan DL, Lichter, AS: Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution. Int J Radiat Oncol Biol Phys 22:361- 367, 1992. PMID: 1740395. 8. Sandler HM, Perez-Tamayo C, Ten Haken RK, Lichter AS: Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformal therapy. Radiotherapy and Oncology 23:53-54, 1992. PMID: 1736332. 9. Sandler HM, Papadopoulos SM, Thornton AF, Ross D: Spinal cord astrocytomas - results of therapy. Neurosurgery 30:490-493, 1992. PMID: 1584345. 10. Herbert SH, Curran WJ Jr, Rosenthal SA, Stafford PM, McKenna WG, Hughes EN, Sandler HM: Adverse influence of younger age on outcome in patients with non-small cell lung carcinoma (NSCLC) treated with radiation therapy (RT) alone. Int J Radiat Oncol Biol Phys 24:37-42, 1992. PMID: 1324900. 11. Curran WJ Jr, Herbert SH, Stafford PM, Sandler HM, Rosenthal S, McKenna WG, Hughes E, Dougherty MJ, Keller S: Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy? Int J Radiat Oncol Biol Phys 24:25-30, 1992. PMID: 1324898. 12. Rosenthal SA, Curran WJ Jr, Herbert SH, Hughes EN, Sandler HM, Stafford PM, McKenna WG: Clinical stage II non-small cell lung cancer (NSCLC) treated with radiation therapy (RT) alone: The significance of clinically staged ipsilateral hilar adenopathy (N1 disease). Cancer 70:2410-2417, 1992. PMID: 1330280. 13. Thornton AF, Sandler HM, Ten Haken RK, McShan DL, Fraass BA, LaVigne ML, Yanke BR: The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. Int J Radiat Oncol Biol Phys 24:767-775, 1992. PMID: 1429103. 14. Ten Haken RK, Thornton AF, Sandler HM, LaVigne ML, Quint DJ, Fraass BA, Kessler ML, McShan DL: A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors. Radiotherapy and Oncology 25:121-133, 1992. PMID: 1332134. 15. Marsh LH, Ten Haken RK, Sandler HM: A customized non-axial external beam technique for treatment of prostate carcinomas. Med Dosim 17:123-127, 1992. PMID: 1388676. 16. Hacker SM, Knight B, Lunde NM, Gratiot-Deans J, Sandler HM, Leichtman AB: A primary central nervous system T-cell lymphoma in a renal transplant patient. The Transplantation 53:691-692, 1992. PMID: 1549870. 17. Grossman HB, Sandler HM, Perez-Tamayo C: Treatment of T3a bladder cancer with iridium implantation. Urology 41:217-220, 1993. PMID: 8442300.

18. Ross DA, McKeever PE, Sandler HM, Muraszko KM: Myxopapillary ependymoma: Report of 13 cases and the results of nucleolar organizing region staining. Cancer 71:3114-3118, 1993. PMID: 8490841. 19. Sandler HM, Bree RL, McLaughlin PW, Grossman HB, Lichter AS: Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys 27:915-919, 1993. PMID: 8244823. 20. Liang BC, Grant R, Junck L, Sandler HM, Papadopoulos SM, Kaminski MS, Greenberg HS: Primary central nervous system lymphoma: Treatment with multiagent systemic and intrathecal chemotherapy with radiation therapy. International Journal of Oncology 3:1001- 1004, 1993. PMID: 21573465. 21. Roa WHY, Hazuka MB, Martel MK, Sandler HM, Thornton AF, Turrisi AT, Urba S, Wolf GT, Lichter AS: Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinus. Int J Radiat Oncol Biol Phys 28:857-865, 1994. PMID: 8138438. 22. Summers RM, Korobkin M, Quint LE, Ellis JH, Grossman HB, Sandler HM, Mandell SH: Pelvic CT findings after radical prostatectomy. J Comput Assist Tomogr 17:767-771, 1993. PMID: 8370832. 23. Sweasey TA, Brunberg JA, McKeever PE, Sandler HM, Chandler WF: Cystic cervical intramedullary ependymoma with previous intracyst hemorrhage: MR imaging at 1.5T. J Neuroimaging 4:111-113, 1994. PMID: 8186527. 24. Grant R, Papadopoulos SM, Sandler HM, Greenberg HS: Metastatic epidural spinal cord compression: Current concepts and treatment. Journal of Neuro-Oncology 19:79-92, 1994. PMID: 7815108. 25. Greenberg HS, Chandler WF, Ensminger WD, Sandler H, Junck L, Page MA, Crane D, McKeever P, Tankanow R, Bromberg J: Radiosensitization with carotid intra-arterial bromodeoxyuridine ± 5-fluorouracil biomodulation for malignant gliomas. Neurology 44:1715-1720, 1994. PMID: 7936303. 26. Polinsky MN, Brunberg JA, McKeever PE, Sandler HM, Telian S, Ross D: Aggressive papillary middle ear tumors: A report of two cases with review of the literature. Neurosurgery 35:493-497, 1994. PMID: 7800140. 27. Balter JM, Sandler HM, Lam K, Bree RL, Lichter AS, Ten Haken RK: Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys 31:113-118, 1995. PMID: 7995741. 28. Pu AT, Sandler HM, Radany EH, Blaivas M, Page MA, Greenberg HS, Junck L, Ross DA: Low grade gliomas: Preliminary analysis of failure patterns among patients treated using 3- D conformal external beam irradiation. Int J Radiat Oncol Biol Phys 31:461-466, 1995. PMID: 7852107. 29. Balter JM, Lam KL, Sandler HM, Littles FJ, Bree RL, Ten Haken RK: Automated localization of the prostate at the time of treatment using implanted radiopaque markers: Technical feasibility. Int J Radiat Oncol Biol Phys 33:1281-1286, 1995. PMID: 7493853. 30. Sandler HM, McLaughlin PW, Ten Haken RK, Addison H, Forman J, Lichter A: 3D conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Bio Phys 33:797-801, 1995. PMID: 7591885. 31. Naida JD, Eisbruch A, Schoeppel SL, Sandler HM, Turrisi AT, Lichter AS: Analysis of localization errors in the definition of the mantle field using a beam's eye view treatment- planning system. Int J Radiat Oncol Bio Phys 35:377-382, 1996. PMID: 8635947.

32. Antonuk LE, Yorkston J, Huang W, Sandler H, Siewerdsen JH and El-Mohri Y: Megavoltage imaging with a large area, flat-panel, amorphous silicon imager. Int J Rad Onc Biol Phys 36:661-72, 1996. PMID: 8948351. 33. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, Strawderman MS, Grijalva KH, Kish KE, Lichter AS: Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 38:311-17, 1997. PMID: 9226317. 34. Martel MK, Sandler HM, Cornblath WT, Marsh LH, Hazuka MB, Roa WH, Fraass BA, Lichter AS: Dose-volume-complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors. Int J Radiat Oncol Bio Phys 38:273-84, 1997. PMID: 9226313. 35. Cooney KA, McCarthy JD, Lange E, Huang L, Montie JE, Sandler HM, Oesterling JE: Hereditary prostate cancer criteria identify families linked to prostate cancer susceptibility locus on 1q. J Natl Cancer Inst 89:955-959, 1997. PMID: 9214675. 36. Narayana V, Roberson PL, Pu T, Sandler H, Winfield RH, McLaughlin PW: Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. Int J Radiat Oncol Biol Phys 37:1181-1185, 1997. PMID: 9169829. 37. Sartor CI, Strawderman MH, Kish KE, McLaughlin PW, Lichter AS, Sandler HM: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Bio Phys 38:941-947, 1997. PMID: 9276358. 38. Kim HK, Thornton AF, Greenberg HS, Page MA, Junck L, Sandler HM: Results of re- irradiation of primary intracranial neoplasms using three-dimensional conformal therapy. Am J Clin Onc (CCT) 20:358-363, 1997. PMID: 9256889. 39. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM: Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. Journal of Clinical Endocrinology & Metabolism 82:3187-91, 1997. PMID: 9329336. 40. Marsh LH, Ten Haken RK, Sandler HM: A single plan approach for differentially dosing sequential target volumes. Med Dosim 22:275-81,1997. PMID: 9503370. 41. Fukunaga-Johnson N, Sandler HM, Marsh R, Martel MK: The use of 3D conformal radiotherapy (3D CRT) to spare the cochlea in patients with medulloblastoma. Int J Radiat Oncol Biol Phys 41:77-82,1998. PMID: 9588920. 42. Ten Haken RK, Fraass BA, Lichter AS, Marsh LH, Radany EH, Sandler HM: A brain tumor dose escalation protocol based on effective dose equivalence to prior experience. Int J Radiat Oncol Biol Phys 42:137-141, 1998. PMID: 9747830. 43. Fukunaga-Johnson N, Lee JH, Sandler HM, Robertson P, McNeil E, Goldwein JW: Patterns of failure following treatment for medulloblastoma: Is it necessary to treat the entire posterior fossa?. Int J Radiat Oncol Biol Phys 42:143-146, 1998. PMID: 9747831. 44. Antonuk LE, El-Mohri Y, Huang W, Jee K-W, Siewerdsen JH, Maolinbay M, Scarpine VE, Sandler H, Yorkston J: Initial performance evaluation of an indirect-detection, active matrix flat-panel imager (AMFPI) prototype for megavoltage imaging. Int J Radiat Oncol Biol Phys 42:437-452, 1998. PMID: 9788427. 45. Ross DA, Sandler HM, Balter JM, Hornick D: Stereotactic radiosurgery of a patient with severe kyphosis: Technical note. J Radiosurgery 1:129-132, 1998. 46. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM: Patterns of failure following high dose 3-D conformal radiotherapy for high grade astrocytomas -- A quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79-88, 1999. PMID: 9989517.

47. Archer PG, Balter JM, Sandler HM, Hayman JA, Ross DA: The treatment planning of segmental, conformal stereotactic radiosurgery utilizing a standard multi-leaf collimator. Med Dosim 24:13-19,1999. PMID: 10100160. 48. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD: The results of radiation therapy in men with clinically localized prostate cancer: An ASTRO sponsored multi-institutional pooled analysis. JAMA: Journal of the American Medical Association. 281:1598-1604, 1999. PMID: 10235152. 49. McLaughlin PW, Wygoda A, Sahijdak W, Sandler HM, Marsh L, Roberson P, Ten Haken RK: The effect of patient position and treatment technique in conformal treatment of prostate cancer. Int J Radiat Oncol Biol Phys 45:407-413, 1999. PMID: 10487564. 50. Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran W: A phase 3 randomized study of radiotherapy plus procarbazine, CCNU and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: A preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys 45:1109-1115, 1999. PMID: 10613302. 51. Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46:391-402, 2000. PMID: 10661346. 52. Fiveash JB, Hanks G, Roach M, Wang S, Vigneault E, McLaughlin PW, Sandler HM: 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review. Int J Radiat Oncol Biol Phys 47:335-342, 2000. PMID: 10802357. 53. Zellars RC, Roberson PL, Strawderman M, Zhang D, Sandler HM, Ten Haken RK, Osher D, McLaughlin PW: Prostate position late in the course of external beam therapy: Patterns and predictors. Int J Radiat Oncol Biol Phys 47:655-660, 2000. PMID: 10837948. 54. Ross DA, Sandler HM, Balter JM, Hayman JA, Deveikis J, Auer DL: Stereotactic radiosurgery of cerebral arteriovenous malformations using a multileaf collimator and a single isocenter. Neurosurgery 47:123-128, 2000. PMID: 10917355. 55. Dawson LA, Litzenberg DW, Brock KK, Sanda M, Sullivan M, Sandler HM, Balter JM: A comparison of ventilatory prostate movement in four treatment positions. Int J Radiat Oncol Biol Phys 48:319-323, 2000. PMID: 10974443. 56. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JMG: Overall survival remains high after PSA failure following conformal external beam radiotherapy. Int J Radiat Oncol Biol Phys 48:629-633, 2000. PMID: 11020557. 57. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899-905, 2000. PMID: 11113727. 58. Taylor JMG, Griffith KA, Sandler HM: Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 50:1212-1219, 2001. PMID: 11483331. 59. Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, Pollack A, Porterfield H, Rifkin M, Roach M 3rd, Sanda M, True L, Vijayakumar S, Winter KA, Zietman A: Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys 51(3 Suppl 2):28-38, 2001. PMID: 11641012.

60. Michalski J. Purdy JA. Gaspar L. Souhami L. Ballow M. Bradley J. Chao CK. Crane C. Eisbruch A. Fallowil D. Forster K. Fowler J. Gillin MT. Graham ML. Harms WB. Huq MS. Kline RW. Mackie TR. Mukherji S. Podogorsak EB. Roach M. Ryu J. Sandler H. Schultz CJ. Schell M. Verhey LJ. Vicini F. Winter KA. Radiation Therapy Oncology Group. Research Plan 2002-2006. Image-Guided Radiation Therapy Committee. Int J Radiat Oncol Biol Phys. 51(3 Suppl 2):60-5, 2001. PMID: 11641018. 61. Hammond ME. Ang K. Byhardt R. Campbell B. Chapman JD. Eisenberg B. Greven K. Harris J. Hoffman J. Lange C. McCormick B. Mehta M. Sandler H. Trotti A. Willet C. Wolfson A. Furness A. Jensen T. Grignon D. Okunieff P. Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Tumor Utilization Committee. Int J of Radiat Oncol, Biol Phys. 51(3 Suppl 2):103-9, 2001. PMID: 11641024. 62. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JM, Litwin MS, Nyquist L, Sanda MG: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557-566, 2002. PMID: 11786586. 63. Litzenberg DW, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, Lam KL, Brock KK and Balter JM: Daily prostate targeting using implanted radio-opaque markers. Int J Radiat Oncol Biol Phys 52:699-703, 2002. PMID: 11849792. 64. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM: Survival and failure patterns of high-grade gliomas following 3-D conformal radiotherapy. J Clin Oncol 20:1635-1642, 2002. PMID: 11896114. 65. Ross DA, Sandler HM, Balter JM, Hayman JA, Archer PG, Auer DL: Imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors. Journal of Neuro-Oncology 56:175-81, 2002. PMID: 11995819. 66. Choo R. Sandler H. Warde P. Hruby G. DeBoer G: Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Canadian Journal of Urology. 9:1479-85, 2002. PMID: 12010592. 67. Pan CC, Kim KY, Taylor JMG, McLaughlin PW, Sandler HM: The influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53:1139-1145, 2002. PMID: 12128113. 68. Chan JL, Kabeto MU, Bennett JE, Oldread AE, Paisley KL, Sandler HM, Smith DC, Hayman JA: Utilities as a measure of the benefit of radiation therapy following orchiectomy for stage I seminoma. Int J Radiat Oncol Biol Phys 53:934-941, 2002. PMID: 12095560. 69. Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, Pollack A, Cox JD. Interim report of toxicity from 3D conformal radiation therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 54:1036-1046, 2002. PMID: 12419429. 70. Law NJ, Taylor JMG, Sandler H. The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure. Biostatistics 3:547-563, 2002. PMID: 12933597. 71. Hruby G, Choo R, Jackson M, Warde P, Sandler H. Management preferences following radical inguinal orchidectomy for Stage I testicular seminoma in Australasia. Australasian Radiology. 46:280-4, 2002. PMID: 12196237. 72. Miller DC, Litwin MS, Sanda MG, Montie JE, Dunn RL, Resh J, Sandler H, Wei JT: Use of quality indicators to evaluate localized prostate cancer care. Cancer 97:1428-35, 2003. PMID: 12627505. 73. Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM: An overview of bladder cancer trials in the radiation therapy oncology group (RTOG). Cancer 97:2115-2119, 2003. PMID: 12673704.

74. Narayan S, Cornblath WT, Sandler HM, Elner V, Hayman JA: Preliminary visual outcomes following three dimensional conformal radiation therapy for optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 56:537-543, 2003. PMID: 12738331. 75. Roach M, Weinberg V, McLaughlin PW, Grossfeld G, Sandler HM: Serum prostatic- specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology 61:730-735, 2003. PMID: 12670556. 76. Michalski J, Winter K, Purdy J, Wilder R, Perez C, Roach M, Parliament M, Pollack A, Markoe A, Harms W, Sandler H, Cox J: Preliminary evaluation of low grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56:192-198, 2003. PMID: 12694838. 77. Tsien C, Griffith KA, Sandler HM, McLaughlin P, Sanda MG, Montie J, Reddy S, Hayman JA: Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology 62:93-98, 2003. PMID: 12837430. 78. Takamiya R, Weinberg V, Young CD, McLaughlin P, Sandler H, Roach M: A zero PSA slope in post-treatment prostate specific antigen supports cure of patients with long term follow-up after external beam radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 56:1073-1078, 2003. PMID: 12829144. 79. DeWitt KD, Sandler HM, Weinberg V, McLaughlin PW, Roach M: What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? Urology 62:492-6, 2003. PMID: 12946753. 80. Ray ME, Dunn RL, Cooney KA, Sandler HM: Family history of prostate cancer and relapse after definitive external beam radiation therapy. Int J Radiat Oncol Biol Phys 57:371-376, 2003. PMID: 12957247. 81. Symon Z, Griffith K, Normolle D, McLaughlin PW, Sullivan M, Sandler HM: Dose escalation for localized prostate cancer: Substantial benefit observed with 3D-conformal therapy. Int J Radiat Oncol Biol Phys 57:384-390, 2003. PMID: 12957249. 82. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz E, Lawton C, Rosenthal SA, Sandler HM, Shipley WU: A phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92- 02. J Clin Oncol 21:3972-3978, 2003. PMID: 14581419. 83. Pan CC, Lee JS, Chan JL, Sandler HM, Underwood W, McLaughlin PW: The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates. Int J Radiat Oncol Biol Phys 57:1292-1296, 2003. PMID: 14630264. 84. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman JL: Long-term multi- institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915-928, 2003. PMID: 14575822. 85. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A: Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929- 943, 2003. PMID: 14575823. 86. Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J: RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? . Int J Radiat Oncol Biol Phys 57:614-620, 2003. PMID: 14529764.

87. Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147-1152, 2004. PMID: 15001257. 88. Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M 3

rd, Sandler HM, Markoe AM, Cox JD. Toxicity after three-dimensional radiotherapy for

prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 58:735-742, 2004. PMID: 14967428. 89. Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM: Neoadjuvant hormone therapy impairs sexual outcome among younger men that undergo external beam radiotherapy for localized prostate cancer. Urology 63:946-950, 2004. PMID: 15134986. 90. Kent E, Sandler H, Montie J, Lee C, Herman J, Esper P, Fardig J, Smith DC: Combined- modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial. J Clin Oncol 22:2540-2545, 2004. PMID: 15226322.. 91. Herman JM, Smith DC, Montie J, Hayman JA, Sullivan MA, Kent E, Griffith KA, Esper P, Sandler HM: Prospective quality of life (QOL) assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology 64:69-73, 2004. PMID: 15245938. 92. Li R, Heydon K, Hammond ME, Grignon DJ, Roach M, Wolkov HB, Sandler HM, Shipley WU, Pollack A: Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10. Clin Cancer Res 10:4118-4124, 2004. PMID: 15217948. 93. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM: Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 22:2133-2140, 2004. PMID: 15169799. 94. Yu M, Law NJ, Taylor JMG, Sandler HM: Joint longitudinal-survival-cure models and their application to prostate cancer. Statistica Sinica 14:835-862, 2004. 95. Sandler HM: Optimizing hormone therapy in localized prostate cancer: Focus on external beam radiotherapy. J Urol 172:S38-41, 2004. PMID: 15535441. 96. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol 172:S3-5, 2004. PMID: 15535434. 97. Kuefer R, Volkmer BG, Loeffler M, Shen RL, Kempf L, Gschwend JE, Hautmann RE, Sandler HM*, Rubin MA*: Comparison of outcome of external radiation therapy versus radical prostatectomy in lymph node positive prostate cancer patients. Prostate Cancer & Prostatic Diseases 7:343-9, 2004. PMID: 15356680. *Sandler and Rubin contributed equally. 98. McLaughlin PW, Narayana V, Meriowitz A, Troyer S,Roberson PL, Gonda R Jr, Sandler H, Marsh L, Lawrence T, Kessler M: Vessel-sparing prostate radiotherapy: Dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys 61:20-31, 2005. PMID: 15629590.

99. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A: Failure definition–dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all? Int J Radiat Oncol Biol Phys 61:409-414, 2005. PMID: 15667960. 100. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A: Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61:415-419, 2005. PMID: 15667961. 101. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL: Definitions of biochemical failure that best predict clinical failure in prostate cancer patients treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173:797- 802, 2005. PMID: 15711272. 102. Taylor JMG, Yu M, Sandler HM: Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol 23:816-825, 2005. PMID: 15681526. 103. Khor LY, DeSilvio M, Al-Saleem T, Hammond ME, Grignon DJ, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A: MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group protocol 8610. Cancer 104:962-967, 2005. PMID: 16007688. 104. Feigenberg SJ, Lee WR, DeSilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H: Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 62:956-964, 2005. PMID: 15989995. 105. Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA ERA. Int J Radiat Oncol Biol Phys 63:795-799, 2005. PMID: 15925452. 106. Chakravarti A, Winter K, Wu C-L, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W: Expression of the epidermal growth factor receptor (EGFR) and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62:309-317, 2005. PMID: 15890569. 107. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimental H, Sandler HM, McLaughlin PW, Wei JT: Long-term outcomes among localized prostate cancer survivors: health-related quality- of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23:2772-2780, 2005. PMID: 15837992. 108. Litzenberg DW, Balter JM, Lam KL, Sandler HM, Ten Haken RK: Retrospective analysis of prostate patients with implanted gold markers using off-line and adaptive therapy protocols. Int J Radiat Oncol Biol Phys 63:123-133, 2005. PMID: 16111580. 109. Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC: Ototoxicity of cisplatin plus standard radiation therapy versus accelerated radiation therapy in glioblastoma patients. J Neuro-Oncol 77:315-320, 2006. PMID: 16273313.

110. Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H: A Phase II study of external beam radiation therapy combined with permanent source brachytherapy for intermediate risk clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys 64:804- 809, 2006. PMID: 16289906. 111. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL: Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups. Int J Radiat Oncol Biol Phys. 65:975-81, 2006. PMID: 16750319. 112. Willoughby TR, Kupelian PA, Pouliot J, Shinohara K, Aubin M, Roach M, Skrumeda LL, Balter JM, Litzenberg DW, Hadley SW, Wei JT, Sandler HM: Target localization and real- time tracking using the Calypso™ system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 65:528-534, 2006. PMID: 16690435. 113. Litzenberg DW, Balter JM, Hadley SW, Sandler HM, Willoughby TR, Kupelian PA, Levine L: Influence of intra-fraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys 65:548-553, 2006. PMID: 16545919. 114. Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin PW, Sanda MG. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology 68:166-171, 2006. PMID: 16844457. 115. Khor LY, DeSilvio M, Li R, McDonnell TJ, Hammond ME, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys. 66:25-30, 2006. PMID: 16814949. 116. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 65:965-974, 2006. PMID: 16798415. 117. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR: Phase III Trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 trials. J Clin Oncol 24:3871-3879, 2006. PMID: 16921039. 118. Lee WR, Bae K, Lawton CA, Gillin MT, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H: A descriptive analysis of postimplant dosimetric parameters from RTOG P0019. Brachytherapy 5:239-243, 2006. PMID: 17118317. 119. Roach M, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW: Defining high risk prostate cancer with risk groups and nomograms: Implications for designing clinical trials. J Urol 176:S16-20, 2006. PMID: 17084158. 120. Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM: Measuring patients’ expectations regarding HRQOL outcomes associated with Prostate cancer surgery or radiotherapy. Urology 68:1224-1229, 2006. PMID: 17141840. 121. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int J Radiat Oncol Biol Phys 67:39-47, 2006. PMID: 17084551.

122. Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM: Post treatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02. IJROBP 66:1064-1071, 2006. PMID: 16979837. 123. Horwitz EM, Levy LB, Thames HD, Kuban DA, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL: The biochemical and clinical significance of the post-treatment PSA bounce for prostate cancer patients treated with external beam radiation therapy alone: A multi-institutional pooled analysis. Cancer 107:1496-1502, 2006. PMID: 16944536. 124. Roach M 3rd, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer 109:213- 220, 2007. PMID: 17167758. 125. Torres-Roca JF, DeSilvio M, Mora-Diaz LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandler H, Pollack A: Activated Stat3 as a correlate of distant metastasis in prostate cancer: A secondary analysis of Radiation Therapy Oncology Group 8610. Urology 69:505-509, 2007. PMID: 17382154. 126. Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer 109:1506-1512, 2007. PMID: 17340591. 127. Spalding AC, Daignault S, Sandler HM, Shah RB, Pan CC, Ray ME: Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Urology 69:936-940, 2007. PMID: 17482938. 128. Roach M 3rd, DeSilvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks G, Shipley WU, Pollack A, Sandler H, Watkins-Bruner D. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: A phase III randomized trial. Int J Radiat Oncol Biol Phys 69:79-87,2007. PMID: 17498886. 129. Williams SG, Taylor JMG, Liu N, Tra Y, Duchesne GM, Kestin LL, Martinez A, Pratt GR, Sandler H: Estimation of the α/β ratio of prostate cancer using the individual fraction size data of 3756 patients. Int J Radiat Oncol Biol Phys 68:24-33, 2007. PMID: 17448868. 130. Miller DC, Spencer BA, Wei JT, Ritchey JD, Stewart AK, Dunn RL, Sandler HM, Litwin MS: Treatment choice and quality of care for men with localized prostate cancer. Med Care 45:401-409, 2007. PMID: 17446826. 131. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM: Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 68:1417-1423, 2007. PMID: 17418972. 132. Lee IH, Roberts R, Shah RB, Wojno K, Wei JT, Sandler HM: Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 68:1059-1064, 2007. PMID: 17398032. 133. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn, Catton CN, DeWeese, TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A: Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041, 2007. PMID: 17513807. 134. Bichakjian CK, Lowe L, Lao, CD, Sandler HM, Bradford CR, Johnson TM, Wong SL: Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management. Cancer 110:1-12, 2007. PMID: 17520670.

135. Khor LY, Moughan J, Al-Saleem T, Hammond EH, Venkatesan V, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Pollack A: Bcl-2 and bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02. Clin Cancer Res 13:3585-3590, 2007. PMID: 17575222. 136. Chakravarti A, DeSilvio M, Zhang M, Grignon D, Rosenthal SA, Asbell S, Hanks G, Sandler H, Khor L-Y, Pollack A, Shipley W: The prognostic value of p16 in locally advanced prostate cancer: A study based on RTOG 9202. J Clin Oncol 25:3082-3089, 2007. PMID: 17634487. 137. Sandler HM, Eisenberger MA: Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol 178:S20-S24, 2007. PMID: 17644123. 138. Kantoff PW, Beer TM, D'Amico AV, DiPaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge conference. J Urol 178:S5-8, 2007. PMID: 17644118. 139. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 5:650-83, 2007. PMID: 17692170. 140. Litzenberg DW, Balter JM, Sandler HM, Wei J, Willoughby TR, Kupelian PA, Cunningham AA, Roach M, Pouliot J: Positional stability of AC electromagnetic Beacon transponders used for prostate localization. Int J Radiat Oncol Biol Phys 68:1199-1206, 2007. PMID: 17513060. 141. Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Dicker AP. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8:912- 920, 2007. PMID: 17881290. 142. Northouse LL, Mood DW, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Sanda MG, Kershaw T. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol 25:4171-4177, 2007. PMID: 17635953. 143. Northouse LL, Mood DW, Schafenacker A, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Kershaw T. Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer 110:2809-2818, 2007. PMID: 17999405. 144. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR: Obesity and prostate cancer-specific mortality following radiation therapy and androgen suppression for locally advanced prostate cancer: An analysis of RTOG 85-31. Cancer 110:2691-2699, 2007. PMID: 17999404. 145. Che M, DeSilvio M, Pollack A, Grignon DJ, Venkatesan VM, Hanks GE, Sandler HM: Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int J Radiat Oncol Biol Phys 69:1117-1123, 2007. PMID: 17689883. 146. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner JA, Demetri GD, Curran WJ, Ganz PA, Kramer B, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey SD, Reaman GH, Sawaya RE, Schuchter L, Sweetenham J, Vahdat LT: Clinical Cancer Advances 2007: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology. JCO 26:313-25, 2008. PMID: 18086794.

147. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters L, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT: HRQOL and satisfaction with cancer treatment outcome from the perspective of early stage prostate cancer patients and their spouse/partners. NEJM 358:1250-1261, 2008. PMID: 18354103. 148. Soto DE, Glaser S, Roberts RH, Schipper MJ, McLaughlin PW, Ray ME, Sandler HM, Pan CC: Impact of pelvic field size and common iliac nodal coverage on treatment outcomes in localized prostate cancer. Urology 71:313-317, 2008. PMID: 18308110. 149. Lee IH, Sadetsky N, Carroll P, Sandler HM: The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. J Urol 179:1072-1076, 2008. PMID: 18206926. 150. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton H, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU: Ten-year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. JCO 26:2497-2504, 2008. PMID: 18413638. 151. Spencer BA, Miller DC, Litwin MS, Ritchey JD, Stewart AK, Dunn RL, Gay EG, Sandler HM, Wei JT. Variations in quality of care for men with early-stage prostate cancer. JCO 26:3735-3742, 2008. PMID: 18669460. 152. Soto DE, Andridge RR, Pan CC, Williams SG, Taylor JMG, Sandler HM: In patients experiencing biochemical failure after radiation therapy pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure free interval. Int J Radiat Oncol Biol Phys 71:1295-1301, 2008. PMID: 18472361. 153. Khor L-Y, Bae K, DeSilvio M, Al-Saleem T, Hammond MEH, Grignon DJ, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A: Protein kinase A RI-alpha (PKA-RIa) predicts prostate cancer outcome: An analysis of Radiation Therapy Oncology Group Trial 86-10. Int J Radiat Oncol Biol Phys 71:1309-1315, 2008. PMID: 18455330. 154. Taussky D, Bae K, Bahary JP, Roach M 3rd, Lawton CA, Shipley WU, Sandler HM: Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of Radiation Therapy Oncology Group Protocol 9413. Urology 72:1125-1129, 2008. PMID: 18314175. 155. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU: Diabetes and mortality in men with locally advanced prostate cancer: Analyses of Radiation Therapy Oncology Group (RTOG) Protocol 92-02. JCO 26:4333-4339, 2008. PMID: 18779620. 156. Herman JM, Pierce LJ, Sandler HM, Griffith KA, Jabbari S, Hiniker SM, Johnson TM: Radiotherapy using a water bath in the treatment of Bowen’s disease of the digit. Radiother Oncol 88:398-402, 2008. PMID: 18571754. 157. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urology 54:816-23, 2008. PMID: 18243498. 158. Proust-Lima C, Taylor JM, Williams SG, Ankerst DP, Liu N, Kestin LL, Bae K, Sandler HM: Determinants of change of prostate-specific antigen over time and its association with recurrence following external beam radiation therapy of prostate cancer in 5 large cohorts. Int J Radiat Oncol Biol Phys 72:782-791, 2008. PMID: 19014779. 159. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton C, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Stephenson AJ, Liauw LS, Scardino PT, Kestin LL, DeWeese TL, Pollack A: A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 72:1298-1302, 2008. PMID: 18672274.

160. Soto DE, Andridge RR, Taylor JM, McLaughlin PW, Sandler HM, Pan CC: Predicting biochemical failure and overall survival through intratherapy PSA changes during definitive external beam radiotherapy. Int J Radiat Oncol Biol Phys 72:1408-1415, 2008. PMID: 18495374. 161. Yu M, Taylor JMG, Sandler HM: Individual prediction in prostate cancer studies using a joint longitudinal survival–cure model. JASA 103:178-187, 2008. 162. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. JCO 27:92-99, 2009. PMID: 19047297. 163. Soto D, Daignault S, Sandler HM, Ray ME: No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73:158-162, 2009. PMID: 18722651. 164. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL: Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology J Clin Oncol 27:812-826, 2009. PMID: 19103723. 165. Gluck I, Vineberg KA, Ten Haken RK, Sandler HM: Evaluating the relationships between rectal normal tissue complication probability (NTCP) and the portion of seminal vesicles (SV) included in the clinical target volume (CTV) in intensity modulated radiotherapy (IMRT) for prostate cancer. Int J Radiat Oncol Biol Phys 73:334-340, 2009. PMID: 19147014. 166. Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group: Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): A randomised clinical trial. Lancet Oncol. 10:467-474, 2009. PMID: 19386548. (Sandler listed as member of PCI Collaborative Group) 167. Souhami L, Bae K, Pilepich M, Sandler H: Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 27:2137-2143, 2009. PMID: 19307511. 168. Kaufman DS, Winter K, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, Zietman AL, Sandler HM: Phase I-II RTOG Study (99-06) transurethral surgery, paclitaxel, cisplatin and followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73:833-837, 2009. PMID: 19100600. 169. Zhang M, Ho A, Hammond EH, Suzuki Y, Scott Bermudez R, Jeffrey Lee R, Pilepich M, Shipley WU, Sandler H, Khor LY, Pollack A, Chakravarti A: Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int J Radiat Oncol Biol Phys 73:1033-1042, 2009. PMID: 18977097. 170. Ray ME, Bae K, Hussain MHA, Hanks GE, Shipley WU, Sandler HM: Potential surrogate endpoints for prostate cancer survival: A secondary analysis of RTOG 92-02. JNCI 101:228-236, 2009. PMID: 19211454. 171. Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM: Phase III multi-institutional trail of adjuvant chemotherapy (CT) with paclitaxel, estramustine, and oral etoposide in combination with long term androgen suppression (AS) therapy and radiation therapy (RT) vs. long term AS + RT alone in the management of high risk prostate cancer: Preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys 73:672-678, 2009. PMID: 18990504.

172. Soto DE, Andridge R, Pan CC, Williams S, Taylor J, Sandler HM: Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancer. Radiother Oncol 90:389-394, 2009. PMID: 18977051. 173. Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A: MDM2 And Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: an analysis of RTOG 92-02. J Clin Oncol 27:3177-3184, 2009. PMID: 19470936. 174. Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM: Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: Long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 74:511-517, 2009. PMID: 18977098. 175. Lawton CAF, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal S, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M, Pisansky TM, Seider M: Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 74:377-382, 2009. PMID: 18947941. 176. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27:4055-4061, 2009. PMID: 19636019. 177. Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM: The importance of protein kinase A in prostate cancer: Relationship to patient outcome in Radiation Therapy Oncology Group Trial 92-02. Clin Cancer Res 15:5478-5484, 2009. PMID: 19706804. 178. Wittman D, Montie J, Hamstra D, Sandler H, Wood D: Counseling patients about sexual health after post-prostatectomy radiation therapy. Int J Impot Res 21:275-284, 2009. PMID: 19609297. 179. Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD: Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 76:14-22, 2010. PMID: 19577865. 180. Jabbari S, Weinberg VV, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M: Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 76:36-42, 2010. PMID: 19409729. 181. Rosenthal SA, Sandler HM: Treatment strategies for high-risk, locally advanced prostate cancer. Nat Rev Urol 7:31-38, 2010. PMID: 20062072. 182. Michalski JM, Lawton C, El Naqa I, Ritter M, O’Meara, E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounoski MK, Ménard C: Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76:361-368, 2010. PMID: 19394158. 183. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A: The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated by external beam radiotherapy between 1987 and 1995. Radiother Oncol 96:6-12, 2010. PMID: 20400191. 184. Sandler HM, Liu P-Y, Dunn RL, Khan DC, Tropper SE, Sanda MG, Mantz CA: Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81 Gy IMRT using reduced PTV margins and electromagnetic tracking: Assessing the impact of margin reduction (AIM) study. Urology 75:1004-1008, 2010. PMID: 20153881.

185. Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott J, Speight J, Vigneault E, Ivker R, Sandler H: Phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: Preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 78:751-758, 2010. PMID: 20207506. 186. Souhami L, Bae K, Pilepich M, Sandler H: Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: A secondary analysis of Radiation Therapy Oncology Group 85-31. Int J Radiat Oncol Biol Phys 78: 1301-1306, 2010. PMID: 20356687. 187. Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H: Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 78:1314-1322, 2010. PMID: 20378270. 188. Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ: Evaluation of nuclear factor kappa B and CXCR4 co-expression in prostate cancer patients in Radiation Therapy Oncology Group (RTOG) 8610. BJU International 108:E51-E58, 2011. PMID: 21156016. 189. Proust-Lima C, Taylor JMG, Sécher S, Sandler H, Kestin L, Pickles T, Bae K, Allison R, Williams S: Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy monotherapy using a post-treatment repeated measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79:195-201, 2011. PMID: 20381268. 190. Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, Cox J: Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys 79:1323-1329, 2011. PMID: 21414514. 191. Bruner DW, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H, Bentzen S, Kachnic L, Berk L: Randomized, double-blinded, placebo- controlled crossover trial of treating erectile dysfunction with sildenafil vs. placebo after radiotherapy and short-term androgen deprivation therapy: Results of RTOG 0215. J Sexual Medicine 8:1228-1238, 2011. PMID: 21235716. 192. Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H: Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys 80:445-452, 2011. PMID: 20615632. 193. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Liebenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU: Radiotherapy and short- term androgen deprivation for localized prostate cancer. NEJM 365:107-118, 2011. PMID: 21751904. 194. Lawton C, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H: Long term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys 81:1-7, 2011. PMID: 21470793. 195. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsy N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA 306:1205-14, 2011. PMID: 21934053. 196. Feng FA, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA, Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys 81:361-367, 2011. PMID: 21820250.

197. Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng FY, Hamstra DA: The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: Evaluation and optimization in patients at higher risk of relapse. Radiother Oncol 101:513-520, 2011. PMID: 21703711. 198. Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra D: Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys 81:335-44, 2011. PMID: 21645976. 199. Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra D: Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 81:351-360, 2011. PMID: 21493015. 200. Oh KS, Hung J, Robertson PL, Garton HJ, Muraszko KM, Sandler HM, Hamstra DA: Outcomes of multidisciplinary management in pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 81:481-488, 2011. PMID: 21470783. 201. Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. Older age predicts decreased metastasis and prostate cancer- specific death for men treated with radiation therapy: Meta-analysis of Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 81:1293-1301, 2011. PMID: 21458924. 202. Qian Y, Feng FY, Schuyler H, Blas K, Sandler HM, Hamstra DA: The percent of positive biopsy cores improves prediction of prostate cancer specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys 81:135-142, 2011. PMID: 21345617. 203. Soto DE, Passarelli MN, Daignault S, Sandler HM. Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys 82:1227-1232, 2012. PMID: 21549519. 204. Litzenberg DW, Balter JM, Hadley SW, Hamstra DA, Willoughby TR, Kupelian PA, Djemil T, Mahadevan A, Jani S, Weinstein G, Solberg T, Enke C, Levine L, Sandler HM: Prostate intra-fraction translation margins for real-time monitoring and correction strategies. Prostate Cancer 2012:130579. PMID: 22111005. 205. Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H: Long-term results of an RTOG phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 82:e795-801, 2012. PMID: 22330999. 206. Kapadia NS, Olson K, Sandler HM, Feng FY, Hamstra DA: Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer 118:2059-2068, 2012. PMID: 22009287. 207. Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD: Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 83:e363-370, 2012. PMID: 22633552. 208. Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W Jr, Gaffney D, Viswanathan AN, Michalski JM. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys 83:e353-362, 2012. PMID: 22483697.

209. Hanisch LJ, Bryan CJ, James JL, Pisansky TM, Corbett T, Parliament MB, Stewart CE, Hartford AC, Sandler H, Berk L, Kachnic L, Bruner DW: Impact of sildenafil on marital and sexual adjustment in patients and their wives after radiotherapy and short-term androgen suppression for prostate cancer: analysis of RTOG 0215. Support Care Cancer 20:2845- 50, 2012. PMID: 22354624. 210. Amro H, Hamstra D, McShan D, Sandler H, Vineberg K, Hadley S, Litzenberg D: The dosimetric impact of prostate rotations during electromagnetically guided external beam radiation therapy. Int J Radiat Oncol Biol Phys 85:230-236, 2013. PMID: 22554583.

211. Vainshtein J, Abu-Isa E, Olson K, Ray ME, Sandler HM, Normolle D, Litzenberg DW, Masi K, Pan C, Hamstra DA: Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: Implications for focal therapy. Radiation Oncology 7:82, 2012. PMID: 22681643. 212. Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA: The addition of low-dose-rate brachytherapy and androgen- deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer 119:681-690, 2013. PMID: 22893254. 213. Howell DD, James JL, Hartsell WF, Suntharalingam M, Machtay M, Suh JH, Demas WF, Sandler HM, Kachnic LA, Berk LB: Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases—Equivalent efficacy, less toxicity, more convenient. Cancer 119:888-896, 2013. PMID: 23165743. 214. Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient- reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119:1729-1735, 2013. PMID: 23436283. 215. Taylor JM, Park Y, Ankerst DP, Proust-Lima C, Williams S, Kestin L, Bae K, Pickles T, Sandler H: Real-time individual predictions of prostate cancer recurrence using joint models. Biometrics 69:206-213, 2013. PMID: 23379600. 216. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence- based practice: Building the National Radiation Oncology Registry. J Oncol Pract. 9:e90- e95, 2013. PMID: 23942508. 217. Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu C, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A: Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. Oncologist 18:685-686, 2013. PMID: 23728940. 218. Hamstra D, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff LA, Zietman AL, Kaplan I, Cieski J, Kuban D, Wei J, Sanda MG, Michalski J: Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient reported outcomes: The PROSTQA experience. Int J Radiat Oncol Biol Phys 86:546-553, 2013. PMID: 23561651. 219. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu I, Krisch RE, Seider MJ, Sandler H, Lawton C: Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer 119:1999-2004, 2013. PMID: 23504930.

220. Feng F, Blas K, Olson K, Stenmark M, Sandler H, Hamstra D: Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 86:64-71, 2013. PMID: 23462420. 221. Kazer MW, Bailey DE, Chipman J, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn R, Crociani C, Sanda MG, PROSTQA Consortium Study Group: Uncertainty and danger among survivors of prostate cancer treatment. BJU Int 111:E84-91, 2013. 222. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys 87:275-281, 2013. PMID: 23886418. 223. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol 8:170, 2013. PMID: 23835115. 224. Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 14:863-872, 2013. PMID: 23823157. 225. Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal C, Litwin M, Kuban D, Hembroff L, Chang P, Sanda MG; the PROSTQA Consortium. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: Results of a multicenter prospective study. Urology 82:1363-9, 2013. PMID: 24139340. 226. Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler HM. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 87:932-8, 2013. PMID: 24113055.

Articles Accepted for Publication

1. Hamstra D, Sandler H, et al. Perineural invasion predicts for increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys. 2. Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB, Sandler HM: Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. JNCI. 3. Hoppe B…Sandler H…Comparative effectiveness study of patient-reported outcomes following proton therapy or IMRT for definitive treatment of prostate cancer. Cancer. 4. Yang W, Fraass BA, Reznik R, Nissen N, Lo S, Jamil LH, Gupta K, Sandler H, Tuli R. Adequacy of inhale/exhale breathhold CT based ITV margins and image-guided registration for free-breathing pancreas and liver SBRT. Radiation Oncology.

Articles Submitted for Publication

1. Robins HI, Berkey B, Prados M, Mehta M, Sandler H, Curran W: Radiographic progression at 6 months as a prognostic endpoint for survival in anaplastic astrocytoma: Analysis of RTOG study 9404.

2. Stephenson AJ, Kattan MW, Scardino PT, Kupelian PA, Kuban DA, Catton CN, Anscher MS, Lin DW, Kestin LL, Valicenti RK, Sandler HM, Michalski JM, Slawin KM, Shariat SF, Forman JD, Zelefsky JM, Pisansky TM, Liauw SL, DeWeese TL, Pollack A: Adjuvant radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. J Clin Oncol. 3. Pan CC, Bae K, Hanks G, Shipley W, Roach M, Lawton CA, Sandler HM: Comparison of two types of ASTRO consensus definitions of biochemical failure: Secondary analysis of Radiation Therapy Oncology Group (RTOG) 92-02 and 94-13. Int J Radiat Oncol Biol Phys. 4. Mirhadi AJ, Chu R, Rudnick J, Yu J, Hakimian B, Phuphanich S, Black K, Sandler H: Does early radiosurgery to residual enhancement improve outcome following subtotal resection of GBM? Neuro-Oncology. 5. Harden J, Sanda MG, Wei JT, Yarandi H, Hembroff L, Hardy J, Northouse L, PROSTQA Study Group: Spouses’ long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction and quality of life 2 years after prostate cancer treatment. J Cancer Survivorship. 6. Kong F, Cuneo KC, Wang L, Bonner JA, Choy H, Gaspar LE, Komaki R, Sun A, West B, Morris DE, Sandler HM, Movsas B. Pract Rad Oncol. 7. Hurley S, Miller T, Flores-Stella R, Dunn K, Schroeder R, Yatawara M, Figlin R, Sandler H, Piantadosi S. Accelerating the clinical trial start-up process for early phase cancer studies: A test of process change to support rapid activation in an academic medical center. J Clin Oncol. 8. Hsu I, Hunt D, Pouliot J, Cunha A, Straube WL, Sandler H: A dosimetric analysis of Radiation Therapy Oncology Group (RTOG) 0321: The importance of urethral dose. Pract Rad Oncol. 9. Gilbert SM, Sanda MG, Dunn RL, Greenfield T, Hembroff L, Klein E, Saigal C, Pisters L, Michalski J, Sandler HM, Litwin MS, Shah N, Wei JT: Providing practitioner-specific outcomes is associated with higher patient satisfaction with information about prostate cancer treatment. Cancer. 10. Mirhadi A, Waxman A, D’Agnolo A, Ih G, Kolb H, Hakimian B, Burnison M, Fraass B, Sandler B: Potential correlation of [F-18]HX4 (a hypoxic tumor marker) PET with treatment response. Clin Nuc Med. 11. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM: Duration of androgen suppression before radiotherapy for localized prostate cancer – Radiation Therapy Oncology Group randomized trial 9910. JAMA.

Non-Peer-Reviewed Publications 1. Lichter AS, Sandler HM, Robertson JM, Lawrence TS, Ten Haken RK, McShan DL, Fraass BA: Clinical experience with 3-dimensional treatment planning. Seminars in Radiation Oncology 2:257-266, 1992. PMID: 10717042. 2. Sandler HM, Ohl DA, Quint LE, Bree RL: Determining local-regional extension of prostate cancer. Seminars in Radiation Oncology 3:169-178, 1993. PMID: 10717068. 3. Sandler HM: 3-D conformal radiotherapy for prostate cancer. The University of Michigan experience. Front Radiat Ther Oncol 29:238-243, 1996. PMID: 8742904. 4. Sandler HM: 3-D conformal radiotherapy for brain tumors. The University of Michigan experience. Front Radiat Ther Oncol 29:250-254, 1996. PMID: 8742906. 5. Baker LH, Hanks G, Gershenson D, Kantoff P, Lange P, Logothetis C, Sandler H, Walsh P. NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology 10:265-88, 1996. PMID: 8953609.

6. Rao G, Sandler H: The Evan Shapiro case study: Stevens-Johnson syndrome. Michigan Oncology Journal Summer 1997. 7. Sandler H, McLaughlin P: Advances in radiotherapy for prostate cancer. Michigan Oncology Journal Fall 1998. 8. Fiveash J, Sandler HM: Controversies in the management of stage I seminoma. Oncology 12:1203-1212, 1998. PMID: 11236311. 9. Fraass BA, Kessler ML, McShan DL, Marsh LH, Watson BA, Dusseau WJ, Eisbruch A, Sandler HM, Lichter AS: Optimization and clinical use of multisegment IMRT for high dose conformal therapy. Seminars in Radiation Oncology 9:60-77. 1999. PMID: 10196399. 10. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD: Radiation therapy for clinically localized prostate cancer. Medical Updates on Therapy, Diagnosis & Prevention, in press 11. Sandler HM: Dose escalation with external beam radiotherapy for prostate cancer. Front Radiat Ther Oncol 34:158-164, 2000. 12. Baker LH, Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG: NCCN Practice Guidelines for prostate cancer. Oncology 14:111- 119, 2000. PMID: 11195405. 13. Sandler HM: Dose escalation for prostate cancer: Which dose for which person?. Front Radiat Ther Oncol 36:10-15, 2002. PMID: 11842740. 14. Michalski JM. Winter K. Purdy JA. Wilder R. Perez CA. Roach M. Parliament M. Pollack A. Markoe A. Harms WB. Sandler H. Cox JD: Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Seminars in Radiation Oncology. 12(1 Suppl 1):75-80, 2002. PMID: 11917289. 15. Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M, Parliament MB, Pollack A, Markoe A, Harms WB, Sandler HM, Cox JD: Grade 2 toxicity on RTOG 9406: Robbing Peter to pay Paul? (eds): Paliwal BR, et al. Biological & Physical Basis of IMRT and Tomotherapy. Madison, WI: Medical Physics Publishing, 2002, 48-54. 16. Narayan S, Smith DC, Sandler HM: Chemotherapy for localized, high risk prostate cancer. Seminars in Radiation Oncology 13:152-157, 2003. PMID: 12728444. 17. Sandler HM, Narayan S, Smith DC: Combined modality treatment for prostate cancer: Role of chemotherapy. Seminars in Radiation Oncology 30(4 Suppl 9):95-100, 2003. PMID: 12908140. 18. Sandler HM, Pienta KJ: Rationale for the Radiation Therapy Oncology Group study RTOG P-0014. Rev Urol. 5(suppl 3):S45-S51, 2003. PMID: 16985950. 19. Tsien C, Sandler H: Salvage radiotherapy in the treatment of prostate cancer. Urology 62 Suppl 1:63-8, 2003. PMID: 14747043. 20. Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG: Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. Current Urology Reports 5:212-219, 2004. PMID: 15161570. 21. Fernando SA, Sandler HM: Organ preservation in muscle invasive bladder cancer. Oncology 19:334-339, 2005. PMID: 15828550.

22. Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM: Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates—the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Seminars in Radiation Oncology 15:36-41, 2005. PMID: 15662605. 23. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin PW, Wei JT: Case illustration on changes in health-related quality of life 4 to 8 years following radical prostatectomy, external radiation and brachytherapy. American Journal of Oncology Review (submitted). 24. Rini BI, Sandler HM, Wood DP: Management of hormone-sensitive non-metastatic prostate cancer. In: Report to the Nation on Prostate Cancer: Focus on Advanced Disease. Prostate Cancer Foundation 2005. 25. Patel AR, Sandler HM, Pienta KJ: Radiation Therapy Oncology Group 0521: A phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin Genitourin Cancer 4:212-214, 2005. PMID: 16425991. 26. Sandler HM: Adjuvant postoperative radiotherapy following radical prostatectomy: is now the time? Nat Clin Pract Oncol. 3:84-85, 2006. PMID: 16462848. 27. Fernando SA, Sandler HM: Multimodality bladder preservation therapy for muscle-invasive bladder tumors. Semin Oncol 34:129-134, 2007. PMID: 17382796. 28. Lee I, Sandler H: Hormone therapy and radiotherapy for intermediate risk prostate cancer. Semin Radiat Oncol 181:7-14, 2008. PMID: 18082583. 29. Oh K, Sandler H: Second malignancies after radiation therapy for prostate cancer: Keeping perspective. Point-Counterpoint. Urology 72:971-973, 2008. PMID: 18817957. 30. Sandler HM, Mirhadi AJ: Radical radiotherapy for prostate cancer is the 'only way to go'. Oncology 23:840-843, 2009. PMID: 19839425. 31. Sandler H: Multimodality bladder preservation in bladder cancer. Commun Oncol 7(suppl 2):31-33, 2010. 32. Sandler HM, Mirhadi AJ: Current status of radiation therapy for bladder cancer. Expert Rev Anticancer Ther 10:895-901, 2010. PMID: 20553213. 33. Sandler HM: Bladder cancer – A condition worthy of clinical investigation. Oncology 25:960-962, 2011. PMID: 22010396. 34. Sandler HM, Mirhadi AJ: Current role of radiation therapy for bladder cancer. Semin Oncol 39:583-587, 2012. PMID: 23040254. Editorials and Letters 1. Sandler HM: Side effects of radiation therapy. J Neurosurg 74:1026-7, 1991. (Letter) 2. Sandler HM, McCallum RW: Re: Markers, CTs, Urethrograms, and the prostatic apex. Int J Radiat Oncol Biol Phys. 31:207-9, 1995. (Letter) 3. McLaughlin PW, Jiroutek MR, Sandler HM: PSA following prostate radiotherapy: How low can you go? J Clin Oncol 14:2889-2890, 1996. (Editorial) 4. Sandler HM: Prostate cancer: patients dilemma? Cancer J Sci Am 4:347-8, 1998. (Editorial) 5. Ray ME, Sandler HM: Review of: D’Amico AV: Combined-modality staging for localized adenocarcinoma of the prostate. Oncology 15:1064-1065, 2001.

6. Sandler HM: High risk prostate cancer: How high is high? Cancer J Sci Am 8:301-2, 2002. (Editorial) 7. Chan JL. Sandler HM. Fraass BA: Radiotherapy dose escalation in high-grade gliomas - Reply. (Letter) J Clin Oncol. 20:3359, 2002. 8. Smith DC, Sandler HM: Review of Raghavan D: Current therapy for testis cancer. Oncology 17:236-237, 2003. 9. Sandler HM, DeSilvio ML: Surrogate end points for prostate cancer: What is PSA telling us? (Editorial) JNCI 95:1352-1353, 2003. 10. D’Amico AV, Sandler HM: The management of a rapidly rising prostate-specific antigen following surgery or radiation therapy. Urologic Oncology 11. Sandler HM: Is prostate cancer like lung cancer? (Editorial) Int J Radiat Oncol Biol Phys 60:1016-1017, 2004. 12. Sandler HM: Adjuvant post-operative radiotherapy following radical prostatectomy: Is now the time? Nature Clinical Practice Oncology 3:84-85, 2006. 13. Sandler HM: Exploring dose-intensity: carefully comparing high-dose with low-dose external-beam radiotherapy for prostate cancer. (Editorial) J Clin Oncol 24:1975-1977, 2006. 14. Pisansky TM, Pollack A, Sandler HM, Valicenti RK: Advanced prostate cancer and postoperative radiotherapy. (Letter) JAMA 297:950-951, 2007. 15. Sandler HM, Lawrence TS. Issue guest editors/Accompanying editorial Cancer Journal 13:287-288, 2007. 16. Sandler HM. Prostate cancer matters. Issue guest editor. Semin Radiat Oncol. 18:1, 2008. 17. Hamstra DA, Michalski JM, Roach M, Sandler HM. Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol. 28:e518-519, 2010. 18. Raghavan D, Steinberg M, Sandler H. Neutron radiotherapy . (Letter) S Afr Med J 102:271, 2012. 19. Sandler HM. Cancer screening isn’t one-size-fits-all. (Editorial) Oncology Times June 15, 2012. Books 1. Greenberg HS, Chandler WF, Sandler HM: Brain Tumors. Philadelphia: FA Davis Co., 1999. 2. Nargund V, Raghavan D, Sandler HM, eds.: Urological Oncology. Springer, 2007. 3. Gulley JL, Dahut WL, Moul JW, Sandler HM, eds. Prostate Cancer: A Clinical Guide. Philadelphia, Penn: Lippincott, Williams & Wilkins; 2007.

4. Gomella L, ed. Five Minute Urology Consult. Consulting Editor. Chapters in Books 1. Greenberg HS, Chandler WF, Ensminger WD, Junck L, Page MA, Thornton AF, Sandler HM, Gebarski SS, McKeever P, Papadopoulos S, Stetson PL, Tankanow R: Radiosensitization with carotid infusion of bromodeoxyuridine +/- 5 fluorouracil biomodulation with external beam radiation for gliomas. (eds): European Review of Biomedical Technology Paris, France: Sepsi Publishing, 1991, Vol 3, Chpt 13, 176-181.

2. Greenberg HS, Chandler WF, Ensminger WD, Junck L, Thornton A, Sandler HM, Page MA, McKeever P, Gebarski S, Liang B, Tankanow R: Radiosensitization with carotid infusion of bromodeoxyuridine +/- 5 fluorouracil (5FU) biomodulation with focal external beam radiation therapy (FEBRT) for malignant gliomas. (eds): Paoletti P, et al. Neuro- Oncology. The Netherlands: Kluwer Academic Publishers, 1991, 217-219. 3. Lichter AS, Sandler HM, Thornton AF, Schoeppel SL, Lawrence TS: Clinical experience with a fully three-dimensional treatment planning system. Volume II: Congressional Proceedings. (eds): Dewey WC, Edington M, Fry RJM, Hall J, Whitmore GF. Radiation Research: A Twentieth-Century Perspective. Academic Press, Inc, 1992. 4. Wilson TG, Pienta KJ, Sandler HM: Prostate cancer. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD: Cancer Management: A Multidisciplinary Approach: Medical, Surgical and Radiation Oncology. Huntington, NY: PRR, Inc., 1996. 5. Pienta KJ, Sandler HM, Wilson TG: Prostate cancer. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD: Cancer Management: A Multidisciplinary Approach: Medical, Surgical and Radiation Oncology, 2

nd edition. Huntington, NY: PRR, Inc., 1998.

6. Sandler HM: Non-axial, external beam treatment for prostate cancer. In: D'Amico A and Hanks GE: Radiotherapeutic Management of Carcinoma of the Prostate. London: Arnold, Ltd, 1999. 7. Pienta KJ, Sandler HM, Sanda MG: Prostate cancer. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD: Cancer Management: A Multidisciplinary Approach: Medical, Surgical and Radiation Oncology, 3

rd edition. Huntington, NY: PRR, Inc., 1999.

8. Chang AE, Johnson TM, Smith DC, Sandler HM: Melanoma. In: Torosian MH: Integrated Cancer Management. New York: Marcel Dekker, Inc., 1999. 9. Lee SW, Sandler HM: The biological effects of ionizing radiation on normal and abnormal nervous systems. In: Crockard A, Hayward R, and Hoff J: Neurosurgery: The Scientific Basis of Clinical Practice, 3

rd edition Oxford: Blackwell Science, Ltd., 2000.

10. Montie JE, Smith DC, Sandler HM: Carcinoma of the bladder. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE: Clinical Oncology, 2

nd. New York: Churchill Livingstone,

2000. 11. Pienta, KJ, Sandler H, Javidan J, Sanda MG: Prostate cancer. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD: Cancer Management: A Multidisciplinary Approach: Medical, Surgical and Radiation Oncology, 7

th edition. Huntington, NY: PRR, Inc., 2003.

12. Pienta, KJ, Sandler H, Hollenbeck B, Sanda MG: Prostate cancer. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD: Cancer Management: A Multidisciplinary Approach: Medical, Surgical and Radiation Oncology, 8

th edition. Huntington, NY: PRR, Inc., 2004.

13. Montie JE, Smith DC, Sandler HM: Carcinoma of the bladder. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG: Clinical Oncology, 3

rd. New York:

Churchill Livingstone, 2004. 14. Sandler HM. Adjuvant androgen deprivation therapy for localized prostate cancer. In: Gulley JL, Dahut WL, Moul JW, Sandler HM, eds. Prostate Cancer: A Clinical Guide. Philadelphia, Penn: Lippincott, Williams & Wilkins; 2007. 15. Smith DC, Montie JE, Sandler HM: Carcinoma of the bladder. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG: Abeloff’s Clinical Oncology, 4

th. New

York: Churchill Livingstone, 2008. 16. Zeng J and Sandler H: Adjuvant and salvage treatment for prostate cancer. In: Hristov B, Lin SH, Christodouleas JP: Radiation Oncology: A Question-Based Review. Lippincott, 2010.

Media 1. Chartrounds, monthly one hour discussions, starting March 2012. 2. “Parker’s Pathways”, Dr. Winn Parker host, radio, one hour interview. September 23, 2012. 3. TalkAboutHealth.com, Expert Q&A Workshop. October 2012. 4. It’s Your Health with Lisa Davis, radio interview. Taped October 10, 2012. Last Update: 12/2013